EP1735447A2 - Proteine de fusion cellulase et construction de fusion cellulase heterologue codant ladite proteine - Google Patents

Proteine de fusion cellulase et construction de fusion cellulase heterologue codant ladite proteine

Info

Publication number
EP1735447A2
EP1735447A2 EP05744703A EP05744703A EP1735447A2 EP 1735447 A2 EP1735447 A2 EP 1735447A2 EP 05744703 A EP05744703 A EP 05744703A EP 05744703 A EP05744703 A EP 05744703A EP 1735447 A2 EP1735447 A2 EP 1735447A2
Authority
EP
European Patent Office
Prior art keywords
cellulase
catalytic domain
heterologous
host cell
fusion construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05744703A
Other languages
German (de)
English (en)
Inventor
Benjamin S. Bower
Edmund A. Larenas
Colin Mitchinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Genencor International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genencor International Inc filed Critical Genencor International Inc
Priority to EP10010133A priority Critical patent/EP2354222A1/fr
Publication of EP1735447A2 publication Critical patent/EP1735447A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01091—Cellulose 1,4-beta-cellobiosidase (3.2.1.91)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Definitions

  • the present invention relates to a heterologous cellulase fusion construct, which encodes a fusion protein having cellulolytic activity comprising a first catalytic domain derived from a fungal exo-cellobiohydrolase and a second catalytic domain derived from a cellulase enzyme.
  • the invention also relates to vectors and fungal host cells comprising the heterologous cellulase fusion construct as well as methods for producing said cellulase fusion protein and enzymatic cellulase compositions.
  • Cellulose and hemicellulose are the most abundant plant materials produced by photosynthesis. They can be degraded and used as an energy source by numerous microorganisms, including bacteria, yeast and fungi, which produce extracellular enzymes capable of hydrolysis of the polymeric substrates to monomeric sugars (Aro et al., 2001). As the limits of non-renewable resources approach, the potential of cellulose to become a major renewable energy resource is enormous (Krishna etal., 2001). The effective utilization of cellulose through biological processes is one approach to overcoming the shortage of foods, feeds, and fuels (Ohmiya et al., 1997).
  • Cellulases are enzymes that hydrolyze cellulose (beta-1 ,4-glucan or beta D- glucosidic linkages) resulting in the formation of glucose, cellobiose, cellooligosaccharides, and the like.
  • Cellulases have been traditionally divided into three major classes: endoglucanases (EC 3.2.1.4) (“EG”), exoglucanases or cellobiohydrolases (EC 3.2.1.91) (“CBH”) and beta-glucosidases ([beta] -D-glucoside glucohydrolase; EC 3.2.1.21) (“BG”) (Knowles et al., 1987 and Hydrin, 1988).
  • Endoglucanases act mainly on the amorphous parts of the cellulose fiber, whereas cellobiohydrolases are also able to degrade crystalline cellulose.
  • Cellulases are known to be produced by a large number of bacteria, yeast and fungi. Certain fungi produce a complete cellulase system capable of degrading crystalline forms of cellulose, such that the cellulases are readily produced in large quantities via fermentation.
  • the complete cellulase system comprising components from each of the CBH, EG and BG classifications is required, with isolated components less effective in hydrolyzing crystalline cellulose (Filho et al., 1996).
  • EG-type cellulases interact to more efficiently degrade cellulose than either enzyme used alone (Wood, 1985; Baker et al., 1994; and Nieves et al., 1995).
  • cellulases are known in the art to be useful in the treatment of textiles for the purposes of enhancing the cleaning ability of detergent compositions, for use as a softening agent, for improving the feel and appearance of cotton fabrics, and the like (Kumar et al., 1997).
  • Cellulase-containing detergent compositions with improved cleaning performance US Pat. No. 4,435,307; GB App. Nos.
  • a heterologous cellulase fusion construct which includes the coding region of a fungal exo-cellobiohydrolase (CBH) catalytic domain fused to a coding region of a cellulase catalytic domain, has been introduced and expressed in a filamentous fungi host cell to increase the yield and effectiveness of cellulase enzymes.
  • CBH fungal exo-cellobiohydrolase
  • the invention includes a heterologous cellulase fusion construct comprising in operable linkage from the 5' end of said construct, (a) a DNA molecule encoding a signal sequence, (b) a DNA molecule encoding a first catalytic domain, wherein said first catalytic domain is derived from of a fungal exo-cellobiohydrolase, and (c) a DNA molecule encoding a second catalytic domain, wherein said second catalytic domain is the catalytic domain of a cellulase enzyme.
  • the heterologous cellulase fusion construct further comprises a linker sequence located 3' of the first catalytic domain and 5' of the second catalytic domain.
  • the heterologous cellulase fusion construct lacks the cellulose binding domain (CBD) of the exo-cellobiohydrolase.
  • the heterologous cellulase fusion construct further comprises a kexin site located after the linker sequence and before the second catalytic domain.
  • the heterologous fusion construct will comprise a promoter of a filamentous fungus secretable protein, said promoter located in operable linkage 5' of the first catalytic domain.
  • the promoter is a cbh promoter and preferably a cbM promoter derived from T. reesei.
  • the first catalytic domain is derived from a CBH1 exo-cellobiohydrolase and particularly a CBH1 having an amino acid sequence of at least 90% sequence identity with the sequence set forth in SEQ ID NO.: 6.
  • the second catalytic domain is an endoglucanase catalytic domain.
  • the second catalytic domain is an exo-cellbiohydrolase catalytic domain.
  • the second catalytic domain is derived from a bacterial cellulase.
  • the second catalytic domain is selected from the group consisting of an Acidothermus cellulolyticus GH5A endoglucanase I (E1 ) catalytic domain; an Acidothermus cellulolyticus GH48 (GH48) cellulase catalytic domain; an Acidothermus cellulolyticus GH74 endoglucanase (GH74-EG) catalytic domain: a Thermobifida fusca E3 (Tf-E3) cellulase catalytic domain; and a Thermobifida fusca E5 endoglucanase (Tf-E5) catalytic domain.
  • E1 Acidothermus cellulolyticus GH5A endoglucanase I
  • GH48 Acidothermus cellulolyticus GH48
  • GH74-EG Acidothermus cellulolyticus GH74 endoglucanase
  • the heterologous cellulase fusion construct lacks the cellulose binding domain of the exo-cellbiohydrolase of the first catalytic domain and the cellulose binding domain of the cellulase of the second catalytic domain.
  • the second catalytic domain is an Acidothermus cellulolyticus GH5A E1 catalytic domain and particularly the Acidothermus cellulolyticus GH5A E1 catalytic domain having an amino acid sequence of at least 90% sequence identity with the sequence set forth in SEQ ID NO. 8.
  • the heterologous cellulase fusion construct comprises a terminator sequence located 3' to the second catalytic domain.
  • the heterologous fusion construct comprises a selectable marker.
  • the invention includes a vector comprising in operable linkage from the 5' end, a promoter of a filamentous fungus secretable protein, a DNA molecule encoding a signal sequence, a DNA molecule encoding a first catalytic domain, wherein said first catalytic domain is derived from a fungal exo- cellobiohydrolase, a DNA molecule encoding a second catalytic domain, wherein said second catalytic domain is the catalytic domain of a cellulase and a terminator.
  • the vector will further include a selectable marker.
  • the vector will comprise a linker located 3' of the first catalytic domain and 5' of the second catalytic domain.
  • the vector will lack the DNA sequence encoding cellulose binding domain of the first catalytic domain.
  • the vector will comprise a kexin site.
  • the second catalytic domain is derived from a bacterial cellulase.
  • the vector lacks the DNA sequence encoding cellulose binding domain of the cellulase of the second catalytic domain.
  • the invention includes a fungal host cell transformed with a heterologous cellulase fusion construct or a fungal host cell transformed with a vector comprising a heterologous cellulase fusion construct as described herein.
  • the invention includes a recombinant fungal cell comprising the heterologous cellulase fusion construct or a vector comprising the same.
  • the fungal host cell is a Trichoderma host cell and more particularly a strain of T reesei.
  • native cellulase genes such as cbhl, cbhl, egll and egl2 have been deleted from the fungal cells.
  • the native cellulose binding domain has been deleted from the fungal cells.
  • the invention includes an isolated cellulase fusion protein having cellulolytic activity which comprises a first catalytic domain, wherein said first catalytic domain is an exo-cellobiohydrolase catalytic domain and a second catalytic domain, wherein said second catalytic domain is derived from a cellulase.
  • the exo-cellobiohydrolase is a CBHL
  • the second catalytic domain is derived from a bacterial cellulase.
  • the bacterial cellulase is an endoglucanase and in another embodiment the bacterial cellulase is an exo-cellobiohydrolase.
  • the bacterial cellulase is derived from a strain of Acidothermus cellulolyticus.
  • the invention concerns a cellulolytic composition comprising the isolated cellulase fusion protein.
  • the invention includes a method of producing an enzyme having cellulolytic activity comprising, a) stably transforming a filamentous fungal host cell with a heterologous cellulase fusion construct or vector as defined above in the first aspect and second aspect; b) cultivating the transformed fungal host cell under conditions suitable for said fungal host cell to produce an enzyme having cellulolytic activity; and c) recovering said enzyme.
  • the filamentous fungal host cell is a Trichoderma cell, and particularly a T. reesei host cell.
  • the exo-cellobiohydrolase is a CBH1 and the cellulase is an Acidothermus cellulolyticus cellulase or a Thermobifida fusca cellulase.
  • the recovered enzyme is a cellulase fusion protein, components of the cellulase fusion protein, or a combination of the cellulase fusion protein and the components thereof.
  • the recovered enzyme(s) is purified.
  • the invention includes a Trichoderma host cell which expresses a cellulase fusion protein, wherein said fusion protein comprises a first catalytic domain, wherein the catalytic domain is derived from an exo-cellobiohydrolase and a second catalytic domain, wherein the second catalytic domain is derived from a cellulase enzyme.
  • the Trichoderma host cell is a T reesei cell.
  • the exo-cellobiohydrolase is a CBH1 and the cellulase is a bacterial cellulase.
  • the bacterial cellulase is derived from an Acidothermus cellulolyticus cellulase and particularly an Acidothermus cellulolyticus E1 , GH48 or GH74 cellulase.
  • the fusion protein will lack the CBD of the cellulase and in other embodiments the fusion protein will include the CBD of the cellulase.
  • the T. reesei host cell includes deleted native cellulase genes.
  • the invention includes a fungal cellulase composition comprising a cellulase fusion protein or components thereof, wherein the fusion protein or components thereof is the product of a recombinant Trichoderma spp.
  • Figure 1 is a representation of a heterologous cellulase fusion construct encompassed by the invention, which includes a Trichoderma reesei cbhl promoter, a cbhl core (cbM signal sequence and cbhl catalytic domain), a cbhl linker sequence, a kexin site, an E1 core (an Acidothermus cellulolyticus E1 endoglucanase catalytic domain), a cbh ⁇ terminator and an A. nidulans amdS selectable marker.
  • Figure 2 is a DNA sequence (SEQ ID NO: 1) of the T.
  • reesei cbhl signal sequence SEQ ID NO: 2
  • T reesei cbhl catalytic domain SEQ ID NO: 3
  • T. reesei cbM linker SEQ ID NO: 4
  • the signal sequence is underlined, the catalytic domain is in bold, and the linker sequence is in italics.
  • Figure 3 shows the predicted amino acid sequence (SEQ ID NO: 5) based on the nucleotide sequence provided in Figure 2, wherein the signal peptide is underlined, the catalytic domain, represented by (SEQ ID NO: 6), is in bold, and the linker is in italics.
  • Figure 4 is an illustration of a nucleotide sequence (SEQ ID NO: 7) encoding an Acidothermus cellulolyticus GH5A endoglucanase I (E1 ) catalytic domain.
  • Figure 5 is the predicted amino acid sequence (SEQ ID NO: 8) of the Acidothermus cellulolyticus GH5A E1 catalytic domain based on the nucleotide sequence provided in Figure 4.
  • Figure 6 is an illustration of a nucleotide sequence (SEQ ID NO: 9) encoding an Acidothermus cellulolyticus GH48 cellulase catalytic domain.
  • Figure 7 is the predicted amino acid sequence (SEQ ID NO: 10) of the Acidothermus cellulolyticus GH48 catalytic domain based on the nucleotide sequence provided in Figure 6.
  • Figures 8A-8B are an illustration of a nucleotide sequence (SEQ ID NO: 11 ) encoding an Acidothermus cellulolyticus GH74- endoglucanase (EG) catalytic domain.
  • Figure 9 is the predicted amino acid sequence (SEQ ID NO: 12) of the Acidothermus cellulolyticus GH74-EG based on the nucleotide sequence provided in Figures 8A and 8B.
  • Figure 10 is an illustration of a nucleotide sequence (SEQ ID NO: 13) encoding the CBD, linker and catalytic domain of a Thermobifida fusca E-3 (TfE-3) cellulase.
  • Figure 11 is the predicted amino acid sequence (SEQ ID NO: 14) of the TfE-3 CBD, linker and catalytic domain based on the nucleotide sequence provided in Figure 10.
  • Figure 12 is an illustration of a nucleotide sequence (SEQ ID NO: 15) encoding the CBD, linker and catalytic domain of a Thermobifida fusca endoglucanase 5 (TfE5).
  • Figure 13 is the predicted amino acid sequence (SEQ ID NO: 16) of the TfE5 CBD, linker and catalytic domain based on the nucleotide sequence provided in Figure 12.
  • Figure 14 is the nucleotide sequence(2656 bases) (SEQ ID NO: 17) of a heterologous cellulase fusion construct described in example 1 comprising, the 7. reesei CBH1 signal sequence; the catalytic domain of the 7. reesei CBH1 ; the 7. reesei CBH1 linker sequence; a kexin cleavage site which includes codons for the amino acids, SKR, and the sequence coding for the Acidothermus cellulolyticus GH5A-E1 catalytic domain.
  • Figure 15 is the predicted amino acid sequence (SEQ ID NO: 18) of the cellulase fusion protein based on the nucleic acid sequence in Figure 14.
  • Figure 16 provides a schematic diagram of the pTrex4 plasmid, which was used for expression of a heterologous fusion cellulase construct (CBH1 -endoglucanase) as described in the examples and includes the Trichoderma reesei cbhl promoter, the 7.
  • CBH1 -endoglucanase heterologous fusion cellulase construct
  • FIG. 17A - E provide the nucleotide sequence (SEQ ID NO: 19) (10239 bp) of the pTrex4 plasmid of Figure 16 excluding the cellulase gene of interest which includes the cellulose catalytic domain.
  • Figure 18 illustrates a SDS-PAGE gel of supernate samples of shake flask growth of clones of a 7. reesei strain deleted for the cellulases, cbM, cbh2, egll and eg/2 and transformed with the CBH1-E1 fusion construct.
  • Lanes 1 and 10 represent MARK 12 Protein Standard (Invitrogen, Carlsbad, CA).
  • Lanes 2 - 8 represent various transformants and lane 9 represents the untransformed 7. reesei strain.
  • the upper arrow indicates the cellulase fusion protein and the lower arrow indicates the cleaved s E1 catalytic domain.
  • Figure 19 illustrates a SDS-PAGE gel of supernate samples of shake flask growth of clones of a 7. reesei strain deleted for the cellulases, cbM, cbh2, eg/1 and egl2 and transformed with the CBH1-GH48 fusion construct. Lanel represents the untransformed control. Lane 2 represents MARK12 Protein Standard (Invitrogen,o Carlsbad, CA). Lanes 3 - 12 represent various transformants. The arrow indicates the CBH1-GH48 fusion protein.
  • Figure 20 illustrates a SDS-PAGE gel of supernate samples of shake flask growth of clones of a 7.
  • Lane 1 represents thes untransformed control.
  • Lane 3 represents MARK 12 Protein Standard (Invitrogen, Carlsbad, CA).
  • Lanes 2 and 4 - 12 represent various transformants.
  • the upper arrow around indicates the CBH1-GH74 fusion protein and the lower arrow indicates the cleaved GH74 catalytic domain.
  • Figure 21 illustrates a SDS-PAGE gel of supernate samples of shake flask0 growth of clones of a 7.
  • FIG. 22 illustrates a SDS-PAGE gel of supernate samples of shake flask growth of clones of a 7. reesei strain deleted for the cellulases, cbM, cbhl, egll and eg/2 and transformed with the CBH1-TfE5 fusion construct.
  • Lanel represents MARK 12 Protein Standard (Invitrogen). Lane 2 represents the untransformed strain and lanes 3 - 12 represent various transformants. Arrows indicate new bands observed in the0 CBH1-TfE5 fusion expressing transformants.
  • Figure 23 illustrates the % cellulose conversion to soluble sugars over time for a 7. reesei parent strain comprising native cellulase genes with a corresponding 7. reesei strain which expresses the CBH1-E1 fusion protein and reference is made to example 3.5 DETAILED DESCRIPTION OF THE INVENTION The invention will now be described in detail by way of reference only using the following definitions and examples.
  • nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.
  • heterologous cellulase fusion construct refers to a nucleic acid construct that is composed of parts of different genes in operable linkage.
  • the components include from the 5' end a DNA molecule encoding a first catalytic domain, wherein said first catalytic domain is a fungal exo-cellobiohydrolase catalytic domain and a DNA molecule encoding a second catalytic domain, wherein said second catalytic domain is a cellulase catalytic domain.
  • cellulase fusion protein or “fusion protein having cellulolytic activity” refers to an enzyme which exhibits cellulolytic activity and which has both a fungal exo- cellobiohydrolase catalytic domain and a cellulase catalytic domain.
  • components of a cellulase fusion protein refers to individual (cleaved) fragments of the cellulase fusion protein, wherein each fragment has cellulolytic activity and includes either the first or the second catalytic domain of the fusion protein.
  • cellulase refers to a category of enzymes capable of hydrolyzing cellulose (beta-1 ,4-glucan or beta D-glucosidic linkages) polymers to shorter cello- oligosaccharide oligomers, cellobiose and/or glucose.
  • exo-cellobiohydrolase CBH refers to a group of cellulase enzyme classified as EC 3.2.1.91. These enzymes are also known as exoglucanases or cellobiohydrolases. CBH enzymes hydrolyze cellobiose from the reducing or non- reducing end of cellulose.
  • a CBH1 type enzyme preferentially hydrolyzes cellobiose from the reducing end of cellulose and a CBH2 type enzyme preferentially hydrolyzes the non-reducing end of cellulose.
  • EG encodedoglucanase
  • An EG enzyme hydrolyzes internal beta-1 ,4 glucosidic bonds of the cellulose.
  • beta-glucosidases refers to a group of cellulase enzymes classified as EC 3.2.1.21.
  • Cellulolytic activity encompasses exoglucanase activity, endoglucanase activity or both types of enzymatic activity.
  • the term “catalytic domain” refers to a structural portion or region of the amino acid sequence of a cellulase which possess the catalytic activity of the cellulase.
  • the catalytic domain is a structural element of the cellulase tertiary structure that is distinct from the cellulose binding site, which is a structural element which binds the cellulase to a substrate such as cellulose.
  • cellulose binding domain refers to a portion of the amino acid sequence of a cellulase or a region of the enzyme that is involved in the cellulose binding activity of a cellulase.
  • Cellulose binding domains generally function by non-covalently binding the cellulase to cellulose, a cellulose derivative or other polysaccharide equivalent thereof.
  • CBDs typically function independent of the catalytic domain.
  • first catalytic domain refers to the catalytic domain of a fungal exo- cellobiohydrolase.
  • second catalytic domain or “cellulase catalytic domain” refers to the catalytic domain of a cellulase enzyme, wherein the cellulase enzyme may be an exo- cellobiohydrolase or an endoglucanase and wherein the catalytic domain is operably linked to the 3' end of the first catalytic domain.
  • a nucleic acid is "operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
  • DNA encoding a signal peptide is operably linked to DNA encoding a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter is operably linked to a coding sequence if it affects the transcription of the sequence.
  • operably linked means that the DNA sequences being linked are contiguous, and, in the case of the heterologous cellulase fusion construct contiguous and in reading frame.
  • the term "gene” means the segment of DNA involved in producing a polypeptide chain, that may or may not include regions preceding and following the coding region, e.g.
  • polypeptide refers to a compound made up of a single chain of amino acid residues linked by peptide bonds.
  • protein as used herein may be synonymous with the term “polypeptide” or may refer, in addition, to a complex of two or more polypeptides.
  • nucleic acid molecule includes
  • RNA, DNA and cDNA molecules are produced.
  • a "heterologous" nucleic acid sequence has a portion of the sequence, which is not native to the cell in which it is expressed.
  • heterologous with respect to a control sequence refers to a control sequence (i.e. promoter or enhancer) that does not function in nature to regulate the same gene the expression of which it is currently regulating.
  • heterologous nucleic acid sequences are not endogenous to the cell or part of the genome in which they are present, and have been added to the cell, by infection, transfection, transformation, microinjection, electroporation, or the like.
  • a "heterologous" nucleic acid sequence may contain a control sequence/DNA coding sequence combination that is the same as, or different from a control sequence/DNA coding sequence combination found in the native cell.
  • the term heterologous nucleic acid sequence encompasses a heterologous cellulase fusion construct according to the invention.
  • the term "vector” refers to a nucleic acid sequence or construct designed for transfer between different host cells.
  • an "expression vector” refers to a vector that has the ability to incorporate and express heterologous DNA sequences in a foreign cell.
  • An expression vector may be generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a target cell.
  • the recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, virus, or nucleic acid fragment. «
  • plasmid refers to a circular double-stranded (ds) DNA construct used as a cloning vector, and which forms an extrachromosomal self- replicating genetic element in many bacteria and some eukaryotes.
  • selectable marker refers to a nucleotide sequence which is capable of expression in cells and where expression of the selectable marker confers to cells containing the expressed gene the ability to grow in the presence of a corresponding selective agent, or under corresponding selective growth conditions.
  • promoter refers to a nucleic acid sequence that functions to direct transcription of a downstream gene. The promoter will generally be appropriate to the host cell in which the target gene is being expressed. The promoter together with other transcriptional and translational regulatory nucleic acid sequences (also termed “control sequences”) are necessary to express a given gene.
  • transcriptional and translational regulatory sequences include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences.
  • signal sequence or “signal peptide” refers to a sequence of amino acids at the N-terminal portion of a protein, which facilitates the secretion of the mature form of the protein outside the cell.
  • the mature form of the extracellular protein lacks the signal sequence which is cleaved off during the secretion process.
  • host cell a cell that contains a heterologous cellulase fusion construct encompassed by the invention or a vector including the same and supports the replication, and/or transcription or transcription and translation (expression) of the heterologous cellulase fusion construct.
  • Host cells for use in the present invention can be prokaryotic cells, such as E. coli, or eukaryotic cells such as yeast, plant, insect, amphibian, or mammalian cells. In general, host cells are filamentous fungi. The term “filamentous fungi” includes all filamentous fungi recognized by those of skill in the art.
  • a preferred fungus is selected from the subdivision Eumycota and Oomycota and particularly from the group consisting of Aspergillus, Trichoderma, " Fusarium, Chrysosporium, Penicillium, Humicola, Neurospora, or alternative sexual forms thereof such as Emericella and Hypocrea (See, Kuhls et al., 1996).
  • the filamentous fungi are characterized by vegetative mycelium having a cell wall composed of chitin, glucan, chitosan, mannan, and other complex polysaccharides, with vegetative growth by hyphal elongation and carbon catabolism that is obligately aerobic.
  • amino acid sequence is an amino acid sequence that is not identical to an original reference amino acid sequence but includes some amino acid changes, which may be substitutions, deletions, additions or the like, wherein the protein exhibits essentially the same qualitative biological activity of the reference protein.
  • An equivalent amino acid sequence will have between 80% - 99% amino acid identity to the original reference sequence.
  • the equivalent amino acid sequence will have at least 85%, 90%, 93%, 95%, 96%, 98% and 99% identity to the reference sequence.
  • substitution results from the replacement of one or more nucleotides or amino acid by different nucleotides or amino acids, respectively.
  • substitutions are usually made in accordance with known conservative substitutions, wherein one class of amino acid is substituted with an amino acid in the same class.
  • a “non-conservative substitution” refers to the substitution of an amino acid in one class with an amino acid from another class.
  • a “deletion” is a change in a nucleotide or amino acid sequence in which one or more nucleotides or amino acids are absent.
  • An “addition” is a change in a nucleotide or amino acid sequence that has resulted from the insertion of one or more nucleotides or amino acid as compared to an original reference sequence.
  • recombinant includes reference to a cell or vector, that has been modified by the introduction of heterologous nucleic acid sequences or that the cell is derived from a cell so modified.
  • recombinant cells express genes that are not found in identical form within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all as a result of deliberate human intervention.
  • the terms "transformed”, “stably transformed” or “transgenic” with reference to a cell means the cell has a heterologous nucleic acid sequence according to the invention integrated into its genome or as an episomal plasmid that is maintained through multiple generations.
  • the term "introduced” in the context of inserting a heterologous cellulase fusion construct or heterologous nucleic acid sequence into a cell means “transfection", “transformation” or “transduction” and includes reference to the incorporation of a heterologous nucleic acid sequence or heterologous cellulase fusion construct into a eukaryotic or prokaryotic cell where the heterologous nucleic acid sequence or heterologous cellulase nucleic acid construct may be incorporated into the genome of the cell (for example, chromosome, plasmid, plastid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (for example, transfected mRNA).
  • the genome of the cell for example, chromosome, plasmid, plastid, or mitochondrial DNA
  • the term "expression” refers to the process by which a polypeptide is produced based on the nucleic acid sequence of a gene. The process includes both transcription and translation. It follows that the term “cellulase fusion protein expression” or “fusion expression” refers to transcription and translation of a "heterologous cellulase fusion construct" comprising a first catalytic domain fused to a second cellulase catalytic domain, the products of which include precursor RNA, mRNA, polypeptide, post- translationally processed polypeptides, and derivatives thereof.
  • purifying generally refers to subjecting recombinant nucleic acid or protein containing cells to biochemical purification and/or column chromatography.
  • the terms “active” and “biologically active” refer to a biological activity associated with a particular protein, such as the enzymatic activity associated with a cellulase. It follows that the biological activity of a given protein refers to any biological activity typically attributed to that protein by those of skill in the art.
  • the term “enriched” means that the concentration of a cellulase enzyme found in a fungal cellulase composition is greater relative to the concentration found in a wild type or naturally occurring fungal cellulase composition. The terms enriched, elevated and enhanced may be used interchangeably herein.
  • a "wild type fungal cellulase composition” is one produced by a naturally occurring fungal source and which comprises one or more BG, CBH and EG components wherein each of these components is found at the ratio produced by the fungal source.
  • a naturally occurring cellulase system may be purified into substantially pure components by recognized separation techniques well published in the literature, including ion exchange chromatography at a suitable pH, affinity chromatography, size exclusion and the like.
  • a purified cellulase fusion protein or components thereof may then be added to the enzymatic solution resulting in an enriched cellulase solution.
  • a heterologous cellulase fusion construct or a vector comprising the heterologous cellulase fusion construct may be introduced into and replicated in a filamentous fungal host cell for protein expression and secretion.
  • the components of the heterologous cellulase fusion construct comprise in operable linkage from the 5' end of said construct, optionally a signal peptide, a DNA molecule encoding a first catalytic domain, wherein said first catalytic domain is derived from a fungal exo-cellobiohydrolase (CBH) and a DNA molecule encoding a second catalytic domain, wherein the second catalytic domain is derived from a cellulase enzyme.
  • CBH fungal exo-cellobiohydrolase
  • the heterologous cellulase fusion comprises in operable linkage from the 5' end of said construct, a signal peptide, a DNA molecule encoding a CBH catalytic domain, a DNA molecule encoding the CBD of a second cellulase catalytic domain, and a DNA molecule encoding the second cellulase catalytic domain, wherein said cellulase second catalytic domain is derived from a bacterial cellulase.
  • the construct will comprise in operable linkage from the 5' end of said construct, a signal peptide, a DNA molecule encoding a catalytic domain of a CBH, optionally a DNA molecule encoding the CBD of the CBH, a linker, optionally a DNA molecule encoding a CBD of a second catalytic domain, and a DNA molecule encoding the second catalytic domain.
  • the heterologous cellulase fusion construct or an expression vector comprises in operable linkage from the 5' end a promoter of a filamentous fungus secretable protein; a DNA molecule encoding a signal sequence; a DNA molecule encoding a first catalytic domain, a linker, optionally a DNA encoding the CBD of a second catalytic domain, a DNA encoding the second catalytic domain, and a terminator.
  • One preferred expression vector will include in operable linkage from the 5' end, a promoter of a filamentous fungus secretable protein, a DNA molecule encoding a fungal exo-cellobiohydrolase signal sequence, a DNA molecule encoding a catalytic domain of an exo-cellobiohydrolase, a linker, a DNA molecule encoding a cellulase catalytic domain, and a terminator.
  • the vector will include the CBD of the exo- cellobiohydrolase and in some embodiments the vector will include the CBD of the cellulase of the second catalytic domain.
  • the coding sequence for the cellulase catalytic domain (either including the cellulase CBD or lacking the cellulase CBD) will not include the cellulase signal sequence.
  • Figures 1 , 14 and 16 as examples of embodiments including an expression vector and heterologous cellulase fusion construct of the invention.
  • Exemplary promoters include both constitutive promoters and inducible promoters. Examples include the promoters from the Aspergillus niger, A awamori or A. oryzae glucoamylase, alpha-amylase, or alpha-glucosidase encoding genes; the A.
  • nidulans gpdA or trpC Genes the Neurospora crassa cbM or trpl genes; the A. niger or Rhizomucor miehei aspartic proteinase encoding genes; the 7. reesei cbM, cbhl, egll, egl2, or other cellulase encoding genes; a CMV promoter, an SV40 early promoter, an RSV promoter, an EF-1 ⁇ promoter, a promoter containing the tet responsive element (TRE) in the tet-on or tet-off system as described (ClonTech and BASF), the beta actin promoter.
  • TRE tet responsive element
  • the promoter is one that is native to the fungal host cell to be transformed.
  • the promoter is an exo-cellobiohydrolase cbM or cbh2 promoter and particularly a cbM promoter, such as a 7. reesei cbM promoter.
  • the T. reesei cbM promoter is an inducible promoter, and reference is made to GenBank Accession No. D86235.
  • the DNA sequence encoding an exo-cellobiohydrolase catalytic domain is operably linked to a DNA sequence encoding a signal sequence.
  • the signal sequence is preferably that which is naturally associated with the exo-cellobiohydrolase to be expressed.
  • the signal sequence is encoded by a Trichoderma ox Aspergillus gene which encodes a CBH. More preferably the signal sequence is encoded by a Trichoderma gene which encodes a CBH1.
  • the promoter and signal sequence of the heterologous cellulase fusion construct are derived from the same source.
  • the signal sequence is a Trichoderma cbM signal sequence that is operably linked to a Trichoderma cbM promoter.
  • the signal sequence has the amino acid sequence of SEQ ID NO: 2 or a sequence having at least 95% identity thereto.
  • CBHs exo-cellobiohydrolases
  • EGs endoglucanases
  • CBD cellulose binding domain
  • linker peptide linker peptide
  • the sequences encoding these enzymes may be used in the heterologous cellulase fusion construct of the invention.
  • the first catalytic domain is derived from a fungal CBH.
  • the CBH is a CBH1 type exo-cellobiohydrolase and in other embodiments the catalytic domain is derived from a CBH2 type exo-cellobiohydrolase.
  • the CBH1 catalytic domain is derived from a Trichoderma spp.
  • the first catalytic domain is encoded by a nucleic acid sequence of a Trichoderma reesei cbM.
  • the nucleic acid is the sequence of SEQ ID NO:3 and nucleotide sequences homologous thereto.
  • the first catalytic domain will have the amino acid sequence of SEQ ID NO: 6 and equivalent amino acid sequences thereto. Further DNA sequences encoding any equivalents of said amino acid sequences of SEQ ID NO: 6, wherein said equivalents have a similar qualitative biological activity to SEQ ID NO: 6 may be incorporated into the heterologous cellulase fusion construct.
  • heterologous cellulase fusion constructs encompassed by the invention will include a linker located 3' to the sequence encoding the exo- cellobiohydrolase catalytic domain and 5' to the sequence encoding the endoglucanase catalytic domain.
  • the linker is derived from the same source as the catalytic domain of the exo-cellobiohydrolase.
  • the linker will be derived from a Trichoderma cbM gene.
  • One preferred linker sequence is illustrated in Figure 3.
  • the heterologous cellulase fusion construct or a an expression vector may include two or more linkers.
  • a linker may be located not only between the coding sequence of the first catalytic domain and the coding sequence of the second catalytic domain, but also between the coding region of the CBD of the second catalytic domain and the coding region of the second catalytic domain.
  • a linker may be between about 5 to 60 amino acid residues, between about 15 to 50 amino acid residues, and between about 25 to 45 amino acid residues.
  • a heterologous cellulase fusion construct or expression vector including a cellulase fusion construct may include a cleavage site, such as a protease cleavage site.
  • the cleavage site is a kexin site which encodes the dipeptide Lys-Arg.
  • the heterologous cellulase fusion constructs include a coding sequence for a second catalytic domain of a cellulase.
  • the cellulase may be from a fungal or bacterial s source. Additionally, the cellulase may be an exo-cellobiohyrolase (CBH) or an endoglucanase (EG).
  • CBH exo-cellobiohyrolase
  • EG endoglucanase
  • the second catalytic domain will be derived from a bacterial cellulase.
  • Source of both CBH and EG cellulases are mentioned above.
  • endoglucanases are found in more than 13 of the Glycosyl Hydrolase families using the classification of Coutinho, P. M. et al. (1999)o Carbohydrate-Active Enzymes (CAZy) server at afmb.cnrs-mrs.fr/ ⁇ cazy/CAZY/index.
  • DNA sequences encoding a second catalytic domain of a bacterial cellulase include: a) the DNA of SEQ ID NO: 7 encoding an Acidothermus cellulolyticus GH5A endoglucanase I (E1 ) catalytic domain having amino acid sequence SEQ ID NO: 8;s b) the DNA sequence of SEQ ID NO: 9 encoding an Acidothermus cellulolyticus GH48 cellulase catalytic domain having amino acid sequence SEQ ID NO: 10; c) the DNA of SEQ ID NO: 11 encoding an Acidothermus cellulolyticus GH74 endoglucanase catalytic domain having amino acid sequence SEQ ID NO: 12; d) the DNA of SEQ ID NO: 13 encoding a Thermobifida fusca E3 cellulaseo having amino acid sequence SEQ ID NO: 14; e) the DNA sequence of SEQ ID NO: 15 encoding a Thermobifida
  • the endoglucanase is an Acidothermus cellulolyticus E1 and reference is made to the an Acidothermus cellulolyticus endoglucanases disclosed in WO 9105039; WO 9315186; USP 5,275,944; WO 9602551 ; USP 5,536,655 and WO 0070031. Also reference is made to GenBank0 U33212.
  • the Acidothermus cellulolyticus E1 has an amino acid sequence of a least 90%, 93%, 95% and 98% sequence identity with the sequence set forth in SEQ ID NO: 6.
  • homologous nucleic acid sequences to the nucleic acid sequences illustrated in SEQ ID NOs: 1 , 3, 7, 9, 11 , 13, and 15 may be used in a5 heterologous cellulase fusion construct or vector according to the invention.
  • Homologous sequences include sequences found in other species, naturally occurring allelic variants and biologically active functional derivatives.
  • a homologous sequence will have at least 80%, 85%, 88%, 90%, 93%, 95%, 97%, 98% and 99% identity to one of the sequences of SEQ ID NOs: 1 , 3, 7, 9, 11 , 13 and 15 when aligned using a sequence alignment program.
  • a homologue of a given sequence has greater than 80% sequence identity over a length of the given sequence e.g., the coding sequence for the Tf-E3 catalytic domain as described herein.
  • the triplet CGT encodes the amino acid arginine.
  • Arginine is alternatively encoded by CGA, CGC, CGG, AGA, and AGG. Therefore it is appreciated that such substitutions in the coding region fall within the nucleic acid sequences covered by the present invention.
  • exemplary computer programs which can be used to determine identity between two sequences include, but are not limited to, the suite of BLAST programs, e.g., BLASTN, BLASTX, and TBLASTX, BLASTP and TBLASTN, publicly available on the Internet at www.ncbi.nlm.nih.gov/BLAST/. See also, Altschul, et al., 1990 and Altschul, et al., 1997.
  • Sequence searches are typically carried out using the BLASTN program when evaluating a given nucleic acid sequence relative to nucleic acid sequences in the GenBank DNA Sequences and other public databases.
  • the BLASTX program is preferred for searching nucleic acid sequences that have been translated in all reading frames against amino acid sequences in the GenBank Protein Sequences and other public databases. Both BLASTN and BLASTX are run using default parameters of an open gap penalty of 11.0, and an extended gap penalty of 1.0, and utilize the BLOSUM- 62 matrix.
  • a preferred alignment of selected sequences in order to determine "% identity" between two or more sequences is performed using for example, the CLUSTAL-W program in MacVector version 6.5, operated with default parameters, including an open gap penalty of 10.0, an extended gap penalty of 0.1 , and a BLOSUM 30 similarity matrix.
  • sequence extension of a nucleic acid encoding a CBH or EG catalytic domain may be carried out using conventional primer extension procedures as described in Sambrook et al., supra, to detect CBH or bacterial EG precursors and processing intermediates of mRNA that may not have been reverse- transcribed into cDNA and/or to identify ORFs that encode the catalytic domain or full length protein.
  • the entire or partial nucleotide sequence of the nucleic acid sequence of the 7. reesei chb ⁇ or GH5a-E1 may be used as a probe. Such a probe may be used to identify and clone out homologous nucleic acid sequences from related organisms.
  • Screening of a cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., (1989). Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al, supra.
  • alignment of amino acid sequences to determine homology or identity between sequences is also preferably determined by using a "sequence comparison algorithm.” Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981 ), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc.
  • the heterologous cellulase fusion construct according to the invention may also include a terminator sequence.
  • the terminator and the promoter are derived from the same source, for example a Trichoderma exo-cellobiohydrolase gene.
  • the terminator and promoter are derived from different sources.
  • the terminator is derived from a filamentous fungal source and particular a Trichoderma.
  • Particularly suitable terminators include cbM derived from a strain of Trichoderma specifically 7.
  • the heterologous fusion construct or a vector comprising the fusion construct may also include a selectable marker.
  • the choice of the proper selectable marker will depend on the host cell, and appropriate markers for different hosts are well known in the art.
  • Typical selectable marker genes include argB from A. nidulans or 7. reesei, amdS from A. nidulans, pyrA from Neurospora crassa or 7. reesei, pyrG from Aspergillus niger or A.
  • nidulans Markers useful in vector systems for transformation of Trichoderma are described in Finkelstein, Chap. 6, in BIOTECHNOLOGY OF FILAMENTOUS FUNGI, Finkelstein et al eds. Butterworth-Heinemann, Boston, MA 1992.
  • the amdS gene from Aspergillus nidulans encodes the enzyme acetamidase that allows transformant cells to grow on acetamide as a nitrogen source (Kelley et al., EMBO J. 4:475-479 (1985) and Penttila et al., Gene 61 :155-164 (1987)).
  • the selectable marker e.g.
  • pyrG may restore the ability of an auxotrophic mutant strain to grow on a selective minimal medium and the selectable marker (e.g. o// ' c31 ) may confer to transformants the ability to grow in the presence of an inhibitory drug or antibiotic
  • a typical heterologous cellulase fusion construct is depicted in Figures 1 and 14. Methods used tojigate a heterologous cellulase nucleic acid construct encompassed by the invention and other heterologous nucleic acid sequences and to insert them into suitable vectors are well known in the art. Linking is generally accomplished by ligation at convenient restriction sites, and if such sites do not exist, synthetic oligonucleotide linkers are used in accordance with conventional practice.
  • vectors can be constructed using known recombination techniques. Any vector may be used as long as it is replicable and viable in the cells into which it is introduced. Large numbers of suitable cloning and expression vectors are described in Sambrook et al., 1989, Ausubel FM et al., 1993, and Strathem et al., 1981 , each of which is expressly incorporated by reference herein. Further appropriate expression vectors for fungi are described in van den Hondel, C.A.M.J.J. et al. (1991) In: Bennett, J.W. and Lasure, L.L. (eds.) More Gene Manipulations in Fungi. Academic Press, pp. 396-428.
  • the appropriate DNA sequence may be inserted into a vector by a variety of procedures.
  • the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by standard procedures.
  • Such procedures and related sub-cloning procedures are deemed to be within the scope of knowledge of those skilled in the art.
  • Exemplary useful plasmids include pUC18, pBR322, pUC100, pSL1180 (Pharmacia Inc., Piscataway, NJ) and pFB6.
  • Other general purpose vectors such as in Aspergillus, pRAX and in Trichoderma, pTEX maybe also be used ( Figures 16 and 17).
  • the filamentous fungal parent or host cell may be a cell of a species of.'but not limited to, Trichoderma sp., Penicillium sp., Humicola sp., Chrysosporium sp., Gliocladium sp., Aspergillus sp., Fusarium sp., Neurospora sp., Hypocrea sp., and Emericella sp.
  • Trichoderma or “Trichoderma sp.” refers to any fungal strains which have previously been classified as Trichoderma or are currently classified as Trichoderma.
  • Trichoderma fungal parent cells include Trichoderma longibrachiatum (reesei), Trichoderma viride, Trichoderma koningii, and Trichoderma harzianum cells.
  • Particularly preferred host cells include cells from strains of 7. reesei, such as RL-P37 (Sheir-Neiss, et al., Appl. Microbiol. Biotechnol. 20:46-53 (1984) and functionally equivalent and derivative strains, such as Trichoderma reesei strain RUT- C30 (ATCC No. 56765) and strain QM9414 (ATCC No. 26921 ). Also reference is made to ATCC No. 13631 , ATCC No. 26921, ATCC No.
  • the strain comprises Aspergillus niger, for example A. niger vat. awamori dgr246 (Goedegebuur et al, (2002) Curr. Genet AV. 89-98) and GCDAP3, GCDAP4 and GAP3-4 (Ward, M, et al., (1993), Appl. Microbiol. Biotechnol. 39:738- 743).
  • a filamentous host cell strain such as a Trichoderma host cell strain which has had one or more cellulase genes deleted prior to introduction of a heterologous cellulase fusion construct encompassed by the invention.
  • Such strains may be prepared by the method disclosed in U.S. Patent No. 5,246,853, U.S. Patent 5,861 ,271 and WO 92/06209, which disclosures are hereby incorporated by reference.
  • a cellulase fusion protein or components thereof having cellulolytic activity in a host microorganism that is missing one or more cellulase genes the identification and subsequent purification procedures are simplified. Any gene from Trichoderma sp.
  • Gene deletion may be accomplished by inserting a form of the desired gene to be deleted or disrupted into a plasmid by methods known in the art.
  • Parental fungal cell lines are generally cultured under standard conditions with media containing physiological salts and nutrients, such as described by Pourquie, J. et al., BIOCHEMISTRY AND GENETICS OF CELLULOSE DEGRADATION, eds. Aubert J.P.
  • yeast Malt Extract (YM) broth, Luria Bertani (LB) broth and Sabouraud Dextrose (SD) broth.
  • a host fungal cell may be genetically modified (i.e., transduced, transformed or transfected) with a heterologous cellulase fusion construct according to the invention, a cloning vector or an expression vector comprising a heterologous cellulase fusion construct.
  • the methods of transformation of the present invention may result in the stable integration of all or part of the construct or vector into the genome of the filamentous fungus. However, transformation resulting in the maintenance of a self- replicating extra-chromosomal transformation vector is also contemplated.
  • Trichoderma Trichoderma or Aspergillus cell line that express large quantities of a heterologous protein.
  • Some of the published methods for the introduction of DNA constructs into cellulase-producing strains of Trichoderma include Lorito, Hayes, DiPietro and Harman (1993) Curr. Genet. 24: 349-356; Goldman, VanMontagu and Herrera-Estrella (1990) Curr. Genet. 17:169-174; Penttila, Nevalainen, Ratto, Salminen and Knowles (1987) Gene 61 : 155-164, EP-A-0 244 234 and also Hazell B.
  • a heterologous cellulase fusion construct or vector into filamentous fungi include, but are not limited to the use of a particle or gene gun (biolistics), permeabilization of filamentous fungi cells walls prior to the transformation process (e.g., by use of high concentrations of alkali, e.g., 0.05 M to 0.4 M CaC1 2 or lithium acetate), protoplast fusion, electroporation, or agrobacterium mediated transformation (US Patent 6,255,115).
  • the invention includes the transformants of filamentous fungi especially Trichoderma cells comprising the coding sequences for the cellulase fusion protein.s
  • the invention further includes the filamentous fungi transformants for use in producing fungal cellulase compositions, which include the cellulase fusion protein or components thereof.
  • the genetically modified cells can be cultured in conventional nutrient media as described above for growth of target host cells and modified as appropriate for activating promoters and selecting transformants.
  • the culture conditions such as temperature, pH and the like, are those previously used for the host cell selected for expression, and will be apparent to those skilled in the art. Also5 preferred culture conditions for a given filamentous fungus may be found in the scientific literature and/or from the source of the fungi such as the American Type Culture Collection (ATCC; "www.atcc.org/"). Stable transformants of filamentous fungi can generally be distinguished from unstable transformants by their faster growth rate and the formation of circular colonieso ' with a smooth rather than ragged outline on solid culture medium.
  • ATCC American Type Culture Collection
  • a further test of stability can be made by growing the transformants on solid non-selective medium, harvesting the spores from this culture medium and determining the percentage of these spores which will subsequently germinate and grow on selective medium.
  • the progeny of cells into which such heterologous cellulase fusion constructs, or vectors including the same, have been introduced are generally considered to comprise the fusion protein encoded by the nucleic acid sequence found in the heterologous cellulase fusion construct.
  • a recombinant strain of filamentous fungi e.g., Trichoderma reesei, comprising a heterologous cellulase fusion construct will produce not only a cellulase fusion protein but also will produce components of the cellulase fusion protein.
  • the recombinant cells including the cellulase fusion construct will produce an increased amount of cellulolytic activity compared to a corresponding recombinant filamentous fungi strain grown under essentially the same conditions but genetically modified to include separate heterologous nucleic acid constructs encoding an exo- cellobiohydrolase catalytic domain and/or a cellulase catalytic domain.
  • the cellulase fusion protein and components thereof include the Trichoderma reesei CBH1 catalytic domain fused to the Acidothermus cellulolyticus E1 catalytic domain and the cleaved CBH1 and E1 products.
  • the cellulase fusion protein and components thereof include the Trichoderma reesei CBH1 catalytic domain fused to the Acidothermus cellulolyticus GH48 cellulase catalytic domain and the cleaved CBH1 and Acidothermus cellulolyticus GH48 products.
  • the cellulase fusion protein and components thereof include the 7. reesei CBH1 catalytic domain fused to a Acidothermus cellulolyticus GH74 endoglucanase catalytic domain and the cleaved CBH1 and GH74 products.
  • the cellulase fusion protein and components thereof include the 7.
  • the cellulase fusion protein and components thereof include the 7 reesei CBH1 catalytic domain fused to a Thermobifida fusca E5 endoglucanase catalytic domain and the cleaved CBH1 and E5 products.
  • assays can be carried out at the protein level, the RNA level or by use of functional bioassays particular to exo-cellobiohydrolase activity or endoglucanase activity and/or production.
  • the following assays can be used to determine integration of cellulase fusion protein expression constructs and vector sequences, Northern blotting, dot blotting (DNA or RNA analysis), RT-PCR (reverse transcriptase polymerase chain reaction), in situ hybridization, using an appropriately labeled probe (based on the nucleic acid coding sequence), conventional Southern blotting and autoradiography.
  • the production and/or expression of a cellulase enzyme may be measured in a sample directly, for example, by assays for cellobiohydrolase or endoglucanase activity, expression and/or production. Such assays are described, for example, in Becker et al., Biochem J.
  • Substrates useful for assaying exo-cellobiohydrolase, endoglucanase or ⁇ - glucosidase activities include crystalline cellulose, filter paper, phosphoric acid swollen cellulose, cellooligosaccharides, methylumbelliferyl lactoside, methylumbelliferyl cellobioside, orthonitrophenyl lactoside, paranitrophenyl lactoside, orthonitrophenyl cellobioside, paranitrophenyl cellobioside.
  • protein expression may be evaluated by immunological methods, such as immunohistochemical staining of cells, tissue sections or immunoassay of tissue culture medium, e.g., by Western blot or ELISA.
  • the cellulase fusion protein which is expressed by the recombinant host cell will be about 0.1 to 80% of the total expressed cellulase. In other embodiments, the amount of expressed fusion protein will be in the range of about 0.1 mg to 100g; about 0.1 mg to 50 g and 0.1 mg to 10g protein per liter of culture media.
  • a cellulase fusion protein or components of the cellulase fusion protein produced in cell culture are secreted into the medium and may be recovered and optionally purified, e.g., by removing unwanted components from the cell culture medium.
  • a cellulase fusion protein or components thereof may be produced in a cellular form necessitating recovery from a cell lysate. In such cases the protein is purified from the cells in which it was produced using techniques 5. routinely employed by those of skill in the art. Examples include, but are not limited to, affinity chromatography (van Tilbeurgh et al., FEBS Lett.
  • Exemplary procedures suitable for such purification include the following: antibody- affinity column chromatography, ion exchange chromatography; ethanol precipitation;o reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; and gel filtration using, e.g., Sephadex G-75.
  • a purified form of a cellulase fusion protein or components thereof may be used to produce either monoclonal or polyclonal antibodies specific to the expressed protein5 for use in various immunoassays. (See, e.g., Hu et al., Mol Cell Biol. vol.1 1 , no. 11, pp. 5792-5799, 1991).
  • Exemplary assays include ELISA, competitive immunoassays, radioimmunoassays, Western blot, indirect immunofluorescent assays and the like.
  • the cellulase fusion protein and components comprising the catalytic domains of the cellulase fusion protein find utility in a wide variety applications, including use in detergent compositions, stonewashing compositions, in compositions for degrading wood pulp into sugars (e.g., for bio-ethanol production), and/or in feed5 compositions.
  • the cellulase fusion protein or components thereof may be used as cell free extracts.
  • the fungal cells expressing a heterologous cellulase fusion construct are grown under batch or continuous fermentation conditions.
  • a classical batch fermentation is a closed system, wherein the composition of the medium is set at the beginning of the fermentation and is not subject to artificial alterations during the fermentation. Thus, at the beginning of the fermentation the medium is inoculated with the desired organism(s). In this method, fermentation is permitted to occur without the addition of any components to the system.
  • a batch fermentation qualifies as a "batch" with respect to the addition of the carbon source and attempts are often made at controlling factors such as pH and oxygen concentration.
  • the metabolite and biomass compositions of the batch system change constantly up to the time the fermentation is stopped. Within batch cultures, cells progress through a static lag phase to a high growth log phase and finally to a stationary phase where growth rate is diminished or halted. If untreated, cells in the stationary phase eventually die.
  • cells in log phase are responsible for the bulk of production of end product.
  • a variation on the standard batch system is the "fed-batch fermentation" system, which also finds use with the present invention.
  • the substrate is added in increments as the fermentation progresses.
  • Fed- batch systems are useful when catabolite repression is apt to inhibit the production of products and where it is desirable to have limited amounts of substrate in the medium. Measurement of the actual substrate concentration in fed-batch systems is difficult and is therefore estimated on the basis of the changes of measurable factors such as pH, dissolved oxygen and the partial pressure of waste gases such as C0 2 . Batch and fed- batch fermentations are common and well known in the art.
  • Continuous fermentation is an open system where a defined fermentation medium is added continuously to a bioreactor and an equal amount of conditioned medium is removed simultaneously for processing.
  • Continuous fermentation generally maintains the cultures at a constant high density where cells are primarily in log phase growth.
  • Continuous fermentation allows for the modulation of one factor or any number of factors that affect cell growth and/or end product concentration.
  • a limiting nutrient such as the carbon source or nitrogen source is maintained at a fixed rate an all other parameters are allowed to moderate.
  • a number of factors affecting growth can be altered continuously while the cell concentration, measured by media turbidity, is kept constant. Continuous systems strive to maintain steady state growth conditions. Thus, cell loss due to medium being drawn off must be balanced against the cell growth rate in the fermentation.
  • the cellulase fusion protein and components thereof find utility in detergent compositions, stonewashing compositions or in the treatment of i fabrics to improve their feel and appearance.
  • a detergent composition refers to a mixture which is intended for use in a wash medium for the laundering of soiled cellulose containing fabrics.
  • a stonewashing composition refers to a formulation for use in stonewashing cellulose containing fabrics. Stonewashing compositions are used to modify cellulose containing fabrics prior to sale, i.e., during the manufacturing process. In contrast, detergent compositions are intended for the cleaning of soiled garments • and are not used during the manufacturing process.
  • compositions may also include, in addition to cellulases, surfactants, additional hydrolytic enzymes, builders, bleaching agents, bleach activators, bluing agents and fluorescent dyes, caking inhibitors, masking agents, cellulase activators, antioxidants, and solubilizers.
  • surfactants may comprise anionic, cationic and nonionic surfactants such as those commonly found in detergents.
  • Anionic surfactants include linear or branched alkylbenzenesulfona.es; alkyl or alkenyl ether sulfates having linear or branched alkyl groups or alkenyl groups; alkyl or alkenyl sulfates; olefinsulfonates; and alkanesulfonates.
  • Ampholytic surfactants include quaternary ammonium salt sulfonates, and betaine-type ampholytic surfactants. Such ampholytic surfactants have both the positive and negative charged groups in the same molecule.
  • Nonionic surfactants may comprise polyoxyalkylene ethers, as well as higher fatty acid alkanolamides or alkylene oxide adduct thereof, fatty acid glycerine monoesters, and the like.
  • Cellulose containing fabric may be any sewn- or unsewn fabrics, yarns or fibers made of cotton or non-cotton containing cellulose or cotton or non-cotton containing cellulose blends including natural cellulosics and manmade cellulosics (such as jute, flax, ramie, rayon, and lyocell).
  • Cotton-containing fabrics are sewn or unsewn fabrics, yarns or fibers made of pure cotton or cotton blends including cotton woven fabrics, cotton knits, cotton denims, cotton yarns, raw cotton and the like.
  • the cellulase compositions comprising the cellulase fusion protein or components thereof are employed from about 0.00005 weight percent to about 5 weight percent relative to the total detergent composition. More preferably, the cellulase compositions are employed from about 0.0002 weight percent to about 2 weight percent relative to the total detergent composition.
  • the rate of hydrolysis of cellulosic products may be increased by using a transformant having a heterologous cellulase fusion construct inserted into the genome, products that contain cellulose or heteroglycans can be degraded at a faster rate and to a greater extent.
  • Products made from cellulose such as paper, cotton, cellulosic diapers and the like can be degraded more efficiently in a landfill.
  • the fermentation product obtainable from the transformants or the transformants alone may be used in compositions to help degrade by liquefaction a variety of cellulose products that add to the overcrowded landfills.
  • Cellulose-based feedstocks are comprised of agricultural wastes, grasses and woods and other low-value biomass such as municipal waste (e.g., recycled paper, yard clippings, etc.).
  • Ethanol may be produced from the fermentation of any of these cellulosic feedstocks. However, the cellulose must first be converted to sugars before there can be conversion to ethanol.
  • a composition containing an enhanced amount of cellulolytic activity due to the inclusion of a cellulase fusion protein or components thereof may find utility in ethanol production
  • Ethanol can be produced via saccharification and fermentation processes from cellulosic biomass such as trees, herbaceous plants, municipal solid waste and agricultural and forestry residues.
  • the ratio of individual cellulase enzymes within a naturally occurring cellulase mixture produced by a microbe may not be the most efficient for rapid conversion of cellulose in biomass to glucose. It is known that endoglucanases act to produce new cellulose chain ends which themselves are substrates for the action of cellobiohydrolases and thereby improve the efficiency of hydrolysis of the entire cellulase system. Therefore, the use of increased or optimized endoglucanase activity from a cellulase fusion protein or components thereof may greatly enhance the production of ethanol and sugar which can be converted by fermentation to other chemicals. Thus, the inventive cellulase fusion protein and components thereof find use in the hydrolysis of cellulose to its sugar components.
  • the cellulase fusion protein or components thereof are added to the biomass prior to the addition of a fermentative organism. In another embodiment, the cellulase fusion protein or components thereof are added to the biomass at the same time as a fermentative organism. Optionally, there may be other cellulase components present in either embodiment.
  • Acidothermus cellulolyticus GH5A endoglucanase I catalytic domain Acidothermus cellulolyticus GH5A endoglucanase I catalytic domain
  • CBH1-48E (7. reesei CBH1 catalytic domain and linker fused to an Acidothermus cellulolyticus GH48 cellulase catalytic domain);
  • CBH1-74E (7. reesei CBH1 catalytic domain and linker fused to an Acidothermus cellulolyticus GH74 endoglucanase catalytic domain);
  • CBH1-TfE3 (7. reesei CBH1 catalytic domain and linker fused to the CBD, linker and catalytic domain of Thermobifida fusca E3 cellulase;
  • CBH1-TfE5 (7. reesei CBH1 catalytic domain and linker fused to the CBD, linker and catalytic domain of Thermobifida fusca E5 endoglucanase; wt% (weight percent); °C (degrees Centigrade); rpm (revolutions per minute); H 2 0
  • EXAMPLE 1 Construction of a CBH1-E1 Fusion Vector
  • the CBH1-E1 fusion construct included the 7. reesei cbhl promoter; the 7. reesei cbhl gene sequence from the start codon to the end of the cbh ⁇ linker and an additional 12 bases of DNA 5' to the start of the endoglucanase coding sequence, a stop codon and the 7. reesei cbM terminator (see Figures 14 and 15).
  • PCT PCT were employed (Sambrook et al., 1989 and 2001 ). The following two primers were used to amplify the coding region of the catalytic domain of the E1 endoglucanase.
  • Reverse Primer 2 EL-317 (containing an Ascl site and stop codon reverse compliment):
  • DNA Polymerase kit (Invitrogen, Carlsbad, CA): 1 ⁇ l dNTP Master Mix (final concentration 0.2mM); 1 ⁇ l primer 1 (final cone 0.5 ⁇ M); 1 ⁇ l primer 2 (final cone 0.5 ⁇ M); 2 ⁇ l DNA template (final cone 50 - 200 ng); 1 ⁇ l 50mM MgS0 4 (final cone 1mM); 5 ⁇ l
  • step 1 - 94°C for 2 min (1st cycle only to denature antibody bound polymerase); step 2 - 94°C for 45 sec; step 3 - 60°C for 30 sec; step 4 - 68°C for 2 min; step 5 - repeated step 2 for 24 cycles and step 6 - 68°C for
  • the ligation mixture was transformed into MM294 competent £ coli cells, plated onto appropriate selection media (LA with 50 ppm carbenicillin) and grown overnight at 37°C. Several colonies were picked from the plate media and grown overnight in 5 ml cultures at 37°C in selection media (LB with 50 ppm carbenicillin) from which plasmid mini-preps were made. Correctly ligated CBH1-E1 fusion vectors were confirmed by restriction digestion.
  • mycelia grown on a PDA plate for 7 days at 28°C was inoculated into 50ml of YEG (5g/L yeast extract plus 20g/L glucose) broth in a 250 ml, 4-baffled shake flask and incubated at 30°C for 16-20 hours at 200 rpm. The mycelia was recovered by transferring the liquid volume into 50ml conical tubes and spinning at 2500 rpm for 10 minutes. The supernatant was aspirated off.
  • YEG yeast extract plus 20g/L glucose
  • the mycelial pellet was transferred into a 250 ml, CA Corning bottle containing 40ml of B glucanase solution and incubated at 30°C, 200 rpm for 2 hrs to generate protoplasts for transformation.
  • Protoplasts were harvested by filtration through sterile miracloth into a 50ml conical tube. They were pelleted by spinning at 2000 rpm for 5 minutes, and the supernatent was aspirated off.
  • the protoplast pellet was washed once with 50ml of 1.2 M sorbitol, spun down, aspirated, and washed with 25ml of sorbitolCaCI 2 .
  • Protoplasts were counted and then pelleted again at 2000 rpm for 5 min, the supernatent was aspirated off, and the protoplast pellet was resuspended in a sufficient volume of sorbitol CaCI 2 to generate a protoplast concentration of 1.25 x 10 8 protoplasts per ml constituting the protoplast solution.
  • Aliquots of up to 20 ⁇ g of expression vector DNA (in a volume no greater than 20 ⁇ l) were placed into 15ml conical tubes and the tubes were put on ice. Then 200 ⁇ l of the protoplast solution was added, followed by 50 ⁇ l PEG solution to each transformation aliquot. The tubes were mixed gently and incubated on ice for 20 min.
  • Acetamide/sorbitol agar ⁇ Part 1 - 0.6g acetamide (Aldrich, 99% sublime.), 1.68g CsCI, 20g glucose, 20g KH 2 PO 4 , 0.6g MgSO 4 -7H 2 O, 0.6g CaCI 2 -2H 2 O, 1 ml 1000 x salts i (see below), adjusted to pH 5.5, brought to volume (300 mis) with dH 2 O, filtered and sterilized.
  • Part II - 20g Noble agar and 218g sorbitol brought to volume (700mls) with dH 2 O and autoclaved. Part II was added to part I for a final volume of 1 L.
  • the concentrations of glucose and lactose were monitored using a glucose oxidase assay kit or a glucose hexokinase assay kit with beta-galactosidase added to cleave lactose, respectively (Instrumentation Laboratory Co., Lexington, MA). Samples were obtained at regular intervals to monitor the progress of the fermentation. Collected samples were spun in a 50ml centrifuge tube at 3/4 speed in an International Equipment Company (Needham Heights, MA) clinical centrifuge. Shake flask grown supernatant samples were run on BIS-TRIS SDS -PAGE gels (Invitrogen), under reducing conditions with MOPS (morpholinepropanesulfonic acid) SDS running buffer and LDS sample buffer. The results are provided in Figure 18.
  • EXAMPLE 3 Assay of Cellulolytic Activity from Transformed Trichoderma reesei Clones The following assays and substrates were used to determine the cellulolytic activity of the CBH1-E1 fusion protein.
  • PCS Pretreated corn stover
  • 2% w/w H 2 SO 4 as described in Schell, D. et al., J. Appl. Biochem. Biotechnol. 105:69 - 86 (2003) and followed by multiple washes with deionized water to obtain a pH of 4.5.
  • Sodium acetate was added to make a final concentration of 50mM and this was titrated to pH 5.0.
  • Measurement of Total Protein - Protein concentration was measured using the bicinchoninic acid method with bovine serum albumin as a standard (Smith P. K. et al., Biochem. 150:76-85, 1985).
  • the cellulose concentration in the reaction mixture was approximately 7%.
  • the enzyme or enzyme mixtures were dosed anywhere from 1 to 60 mg of total protein per gram of cellulose.
  • the percent conversion of 13.8% PCS (7.06% cellulose) at 55°C for 1 day was evaluated using 10 mg enzyme/g cellulose in 50 mM acetate buffer at 55°C.
  • Samples were agitated at 700 rpm. Comparisons were made between supernatants from growth of 1 ) a 7 reesei parent strain which included the native cellulase genes and 2) a corresponding 7. reesei CBH1-E1 fusion strain transformed according to the examples herein. Samples were quenched at various times up to 24 hours.
  • the CBH1-48E fusion construct was designed according to the procedures described below in example 1 with the following differences.
  • the forward primer was designed to maintain the reading frame translation and include a Lys-Arg kexin cleavage site (underlined) at the end of the cbM linker sequence.
  • the reverse primer contained a stop codon at the end of the GH48E. Primers were ordered with 5 prime phosphates to enable subsequent blunt cloning.
  • the GH48 catalytic domain was amplified with the following forward and reverse primers:
  • Amplification was performed using Stratagene's Herculase High Fidelity Polymerase (Stratagene, La Jolla, CA). An annealing temperature of 65°C was used. A DNA plasmid encompassing the GH48 catalytic domain was used as the template for PCR (approximately 0.2 ug of DNA). An equivalent method for isolating the GH48 gene is described in U.S. Pat. Appln. No. 2003/0096342.
  • the CBH1-74E fusion construct was designed according to the procedures described above in example 1 with the following differences.
  • the forward primer was designed to maintain the reading frame translation and include a Lys-Arg kexin cleavage site (underlined).
  • the reverse primer encodes a stop codon (the reverse compliment - underlined) at the end of the catalytic domain. Primers were ordered with 5 prime phosphates to enable subsequent blunt cloning.
  • the GH74 catalytic domain was amplified with the following forward and reverse primers: GH74 forward bluntF4 -
  • GCTTATGGCGCGCCTTACAGAGGCGGGTAGGCGTTGG SEQ ID NO: 28.
  • the plasmid containing the TfE3 gene was used as the DNA template for amplification.
  • An equivalent template DNA is described in Zhang, S. et al., Biochem.
  • EL-308 (which contains a Spel site) - forward primer GCTTATACTAGTAAGCGCGCCGGTCTCACCGCCACAGTCACC (SEQ ID NO: 29) and EL-309 (which contains a Ascl site) reverse primer - GCTTATGGCGCGCCTCAGGACTGGAGCTTGCTCCGC (SEQ ID NO: 30). Transformation was as described above. The highest level of cleaved TfE5 protein expression from a transformant in shake flasks was estimated to be greater than 2 g/L.
  • ACEII a novel transcriptional activator involved in regulation of cellulase and xylanase genes of Trichoderma reesei. J Biol Chem. 2001 Jun 29;276(26):24309-14. (Epub 2001 Apr 13.) Aubert J.P. et al, p11 et seq., Biochemistry and Genetics of Cellulose Degradation, eds. Aubert, J. P., Beguin, P., Millet, J., Federation of European Microbiological Societies, Academic Press, 1988. Ausubel G. M., et al. CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1993.
  • Saloheimo M et al., Gene 63:11-22, 1988. Saloheimo, A. et al., Molecular Microbiology, 13:219-228, 1994. Saloheimo, M. et al., Eur. J. Biochem., 249:584-591 , 1997. Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL (Second Edition), Cold Spring Harbor Press, Plainview, N.Y., 1989.
  • Hydrin Methods Enzymol., 160, 25, pages 234 et seq, 1988. Scopes, Methods Enzymol. 90 Pt E:479-90, 1982. Shoemaker et al., Biochem. Biophys. Acat.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne une construction de fusion cellulase hétérologue codant une protéine de fusion présentant une activité cellulolytique, comprenant un premier domaine catalytique issu d'une exo-cellobiohydrolase fongique et un deuxième domaine catalytique issu d'une enzyme cellulase. L'invention concerne également des vecteurs et des cellules hôtes fongiques comprenant ladite construction de fusion cellulase hétérologue, ainsi que des procédés de production de cette protéine de fusion cellulase et des compositions cellulase enzymatiques.
EP05744703A 2004-03-25 2005-03-25 Proteine de fusion cellulase et construction de fusion cellulase heterologue codant ladite proteine Withdrawn EP1735447A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10010133A EP2354222A1 (fr) 2004-03-25 2005-03-25 Protéine de fusion de cellulase et construction de fusion de cellulose hétérologue la codant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55671104P 2004-03-25 2004-03-25
PCT/US2005/010242 WO2005093050A2 (fr) 2004-03-25 2005-03-25 Proteine de fusion cellulase et construction de fusion cellulase heterologue codant ladite proteine

Publications (1)

Publication Number Publication Date
EP1735447A2 true EP1735447A2 (fr) 2006-12-27

Family

ID=35033698

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05744703A Withdrawn EP1735447A2 (fr) 2004-03-25 2005-03-25 Proteine de fusion cellulase et construction de fusion cellulase heterologue codant ladite proteine
EP10010133A Ceased EP2354222A1 (fr) 2004-03-25 2005-03-25 Protéine de fusion de cellulase et construction de fusion de cellulose hétérologue la codant

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP10010133A Ceased EP2354222A1 (fr) 2004-03-25 2005-03-25 Protéine de fusion de cellulase et construction de fusion de cellulose hétérologue la codant

Country Status (6)

Country Link
EP (2) EP1735447A2 (fr)
JP (1) JP5114194B2 (fr)
CN (1) CN1930294A (fr)
BR (1) BRPI0509212A (fr)
CA (1) CA2560588A1 (fr)
WO (1) WO2005093050A2 (fr)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097445B2 (en) * 2004-03-25 2012-01-17 Danisco Us Inc. Exo-endo cellulase fusion protein
DK1838849T3 (en) 2004-12-30 2015-11-30 Danisco Us Inc CBH2 CELLULASE VARIETIES OF HYPOCREA JECORINA
CA2658610A1 (fr) 2006-07-21 2008-05-15 Novozymes, Inc. Procedes d'augmentation de la secretion de polypeptides ayant une activite biologique
CA2672603A1 (fr) 2006-12-18 2008-06-26 Danisco Us, Inc., Genencor Division Nouvelles compositions de laccases, et leurs methodes d'utilisation
JP2009033993A (ja) * 2007-07-31 2009-02-19 Toyota Central R&D Labs Inc セルラーゼ担持材料及びその利用
CN101952420A (zh) 2007-12-19 2011-01-19 诺维信公司 具有纤维素分解增强活性的多肽和编码该多肽的多核苷酸
BRPI0922773B1 (pt) 2008-12-04 2018-10-09 Novozymes As célula microbiana hospedeira transgênica, métodos para produzir um polipeptídeo tendo atividade de intensificação celulolítica e para degradar ou converter um material celulósico, construção de ácido nucleico, vetor de expressão, e, composição detergente.
CA2747056A1 (fr) 2008-12-19 2010-07-15 Novozymes, Inc. Procedes permettant l'augmentation du taux d'hydrolyse enzymatique de materiau cellulosique en presence d'une peroxydase
US8338121B2 (en) 2008-12-19 2012-12-25 Novozymes, Inc. Methods for determining cellulolytic enhancing activity of a polypeptide
EP2379712B1 (fr) 2008-12-19 2017-02-22 Novozymes Inc. Procédés destinés à augmenter l'hydrolyse de matériaux cellulosiques en présence de la cellobiose déshydrogénase
WO2010080407A2 (fr) 2008-12-19 2010-07-15 Novozymes, Inc. Procédés permettant l'augmentation du taux d'hydrolyse de matériau cellulosique
US8604277B2 (en) 2009-01-28 2013-12-10 Novozymes, Inc. Polypeptides having beta-glucosidase activity and polynucleotides encoding same
US8629324B2 (en) 2009-01-30 2014-01-14 Novozymes, Inc. Polypeptides having expansin activity and polynucleotides encoding same
CN102365360A (zh) 2009-03-24 2012-02-29 诺维信公司 具有乙酰木聚糖酯酶活性的多肽和编码该多肽的多核苷酸
EP2435561B1 (fr) 2009-05-29 2018-08-08 Novozymes Inc. Procédés d'amélioration de la dégradation ou de la conversion de matière cellulosique
ES2534078T3 (es) 2009-06-02 2015-04-17 Novozymes Inc. Polipéptidos con actividad de celobiohidrolasa y polinucleótidos que codifican los mismos
WO2011005867A1 (fr) 2009-07-07 2011-01-13 Novozymes, Inc. Polypeptides ayant une activité cellulolytique améliorée et polynucléotides codant pour ceux-ci
DK3269804T3 (da) 2009-09-17 2020-11-23 Novozymes Inc Polypeptider med cellulolyseforbedrende aktivitet og polynukleotider, som koder for dem
WO2011035029A1 (fr) 2009-09-18 2011-03-24 Novozymes, Inc. Polypeptides à activité bêta-glucosidase et polynucléotides codant pour lesdits polypeptides
MX353237B (es) 2009-09-23 2018-01-08 Danisco Us Inc Enzimas de glicosil hidrolasa novedosas y usos de las mismas.
US8211665B2 (en) 2009-09-29 2012-07-03 Novozymes, Inc. Polypeptides having xylanase activity and polynucleotides encoding same
CA2775358A1 (fr) 2009-09-29 2011-04-07 Novozymes A/S Polypeptides presentant une activite favorisant l'activite cellulolytique et polynucleotides codant pour ceux-ci
CN102666846A (zh) 2009-09-30 2012-09-12 诺维信公司 具有纤维素分解增强活性的多肽和编码该多肽的多核苷酸
DK2483296T3 (en) 2009-09-30 2015-11-02 Novozymes Inc Polypeptides having cellulolytic enhancing activity and polynucleotides encoding them
WO2011050037A1 (fr) 2009-10-23 2011-04-28 Novozymes, Inc. Variants d'une cellobiohydrolase et polynucléotides codant pour ceux-ci
US20120260371A1 (en) 2009-10-29 2012-10-11 Novozymes A/S Polypeptides Having Cellobiohydrolase Activity and Polynucleotides Encoding Same
CN102947442B (zh) 2009-11-06 2016-03-09 诺维信股份有限公司 用于糖化纤维素材料的组合物
US9267125B2 (en) 2009-11-06 2016-02-23 Novozymes, Inc. Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
CA2780198A1 (fr) 2009-11-06 2011-05-12 Novozymes, Inc. Polypeptides presentant une activite xylanase et polynucleotides codant pour ceux-ci
CN102686736B (zh) 2009-12-23 2017-05-31 丹尼斯科美国公司 提高同步糖化发酵反应效率的方法
WO2011123450A1 (fr) 2010-03-31 2011-10-06 Novozymes, Inc. Variants de cellobiohydrolase et polynucléotides codant pour ceux-ci
WO2012003379A1 (fr) 2010-06-30 2012-01-05 Novozymes A/S Polypeptides présentant une activité de beta-glucosidase et polynucléotides codant pour ceux-ci
WO2012021395A1 (fr) 2010-08-12 2012-02-16 Novozymes, Inc. Compositions comprenant un polypeptide à activité renforçant l'activité cellulolytique, composé contenant du soufre et utilisations correspondantes
WO2012030811A1 (fr) 2010-08-30 2012-03-08 Novozymes A/S Polypeptides ayant une activité cellobiohydrolase et polynucléotides codant pour ceux-ci
US9267126B2 (en) 2010-08-30 2016-02-23 Novozymes, Inc. Polypeptides having endoglucanase activity and polynucleotides encoding same
US20130212746A1 (en) 2010-08-30 2013-08-15 Novoyzmes A/S Polypeptides Having Hemicellulolytic Activity And Polynucleotides Encoding Same
EP2735611B1 (fr) 2010-08-30 2018-11-21 Novozymes A/S Polypeptides dotés d'activité d'amélioration cellulolytique et polynucléotides les codant
WO2012030849A1 (fr) 2010-08-30 2012-03-08 Novozymes A/S Polypeptides présentant une activité xylanase et polynucléotides codant ces polypeptides
WO2012030845A2 (fr) 2010-08-30 2012-03-08 Novozymes A/S Polypeptides présentant une activité bêta-glucosidase, une activité bêta-xylosidase, ou une activité bêta-glucosidase et bêta-glucosidase, et polynucléotides codant pour ceux-ci
DK2622068T3 (en) 2010-09-30 2016-10-17 Novozymes Inc Variants of polypeptides having cellulolytic enhancing ACTIVITY AND POLYNUCLEOTIDES ENCODING THEM
WO2012044836A1 (fr) 2010-09-30 2012-04-05 Novozymes, Inc. Variantes de polypeptides présentant une activité cellulolytique et polynucléotides codant pour celles-ci
DK2622069T3 (en) 2010-10-01 2016-02-22 Novozymes Inc Beta-glucosidasevarianter and polynucleotides encoding them
US9122085B2 (en) 2010-10-07 2015-09-01 Alcatel Lucent Thermally controlled semiconductor optical waveguide
US20130260423A1 (en) 2010-10-26 2013-10-03 Novozymes North America, Inc. Methods of Saccharifying Sugar Cane Trash
CN103282504A (zh) 2010-11-02 2013-09-04 诺维信股份有限公司 用家族61多肽预处理纤维素材料的方法
EP2635594B1 (fr) 2010-11-04 2017-01-11 Novozymes Inc. Polypeptides présentant une activité de cellobiohydrolase et polynucléotides codant pour ceux-ci
BR112013009026A2 (pt) 2010-11-12 2016-07-12 Novozymes Inc polipeptídeo isolado, célula hospedeira recombinante, métodos para produzir um polipeptídeo, um mutante de uma célula precursora, uma proteína, e um produto de fermentação, para inibir a expressão de um polipeptídeo, para degradar ou converter um material celulósico, e método para fermentar um material celulósico, planta transgênica, parte de planta ou célula de planta, molécula de rna inibidora de filamento duplo, polinucleotídeo isolado, e, formulação de caldo integral ou composição de cultura de célula
DK2640833T3 (en) 2010-11-18 2016-11-28 Novozymes Inc Chimeric polypeptides having cellulolytic enhancing ACTIVITY AND POLYNUCLEOTIDES ENCODING THEM
US8927235B2 (en) 2010-12-06 2015-01-06 Novozymes A/S Methods of hydrolyzing oligomers in hemicellulosic liquor
EP2668266B1 (fr) 2011-01-26 2018-01-03 Novozymes A/S Polypeptides ayant une activité cellobiohydrolase et polynucléotides codant pour ceux-ci
DK2668267T3 (da) 2011-01-26 2018-01-29 Novozymes Inc Polypeptider med cellobiohydrolaseaktivitet og polynukleotider, som koder for dem
MX337942B (es) 2011-01-26 2016-03-29 Novozymes As Polipeptidos que tienen actividad de endoglucanasa y polinucleotidos que codifican los mismos.
MX2013007720A (es) 2011-01-26 2013-08-09 Novozymes As Polipeptidos que tienen actividad celobiohidrolasa y polinucleotidos que codifican para los mismos.
MX337919B (es) 2011-01-26 2016-03-28 Novozymes As Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos.
CN103459605B (zh) 2011-01-31 2016-08-24 诺维信北美公司 用于酶法精制经预处理的纤维素材料以供糖化的工艺
MX2013007997A (es) 2011-02-23 2013-08-21 Novozymes Inc Polipeptidos que tienen actividad de incremento celulolitico y polinucleotidos que codifican para los mismos.
US9150842B2 (en) 2011-03-09 2015-10-06 Novozymes A/S Methods of increasing the cellulolytic enhancing activity of a polypeptide
WO2012122477A1 (fr) 2011-03-10 2012-09-13 Novozymes A/S Polypeptides ayant une activité améliorant l'activité cellulolytique et polynucléotides codant pour ceux-ci
CN103842515A (zh) 2011-03-17 2014-06-04 丹尼斯科美国公司 降低糖化过程的粘度的方法
DK2689011T3 (en) 2011-03-25 2018-01-22 Novozymes As PROCEDURE FOR DEGRADATION OR CONVERSION OF CELLULOSE-SUBSTANCING MATERIAL
US20140080182A1 (en) 2011-03-31 2014-03-20 Novozymes, Inc. Cellulose Binding Domain Variants and Polynucleotides Encoding Same
US9410136B2 (en) 2011-03-31 2016-08-09 Novozymes, Inc. Methods for enhancing the degradation or conversion of cellulosic material
US9926547B2 (en) 2011-04-28 2018-03-27 Novozymes, Inc. Polypeptides having endoglucanase activity and polynucleotides encoding same
WO2012149344A1 (fr) 2011-04-29 2012-11-01 Novozymes, Inc. Procédés pour améliorer la dégradation ou la conversion de matériau cellulosique
EP2710132A1 (fr) 2011-05-19 2014-03-26 Novozymes, Inc. Procédés d'accélération de la dégradation de la matière cellulosique avec des protéines de liaison à la chitine
EP2710133A1 (fr) 2011-05-19 2014-03-26 Novozymes, Inc. Procédés pour augmenter la dégradation de matériau cellulosique avec des protéines de liaison de chitine
BR112013032861A2 (pt) 2011-07-22 2017-01-24 Novozymes North America Inc métodos para aumentar a atividade da enzima celulolítica durante a hidrólise do material celulósico, para hidrolisar um material celulósico pré-tratado, para a produção de um produto da fermentação, e para a fermentação de um material celulósico pré-tratado
US8859227B2 (en) 2011-08-04 2014-10-14 Novozymes, Inc. Polypeptides having xylanase activity and polynucleotides encoding same
DK2739728T3 (en) 2011-08-04 2017-10-16 Novozymes As Polypeptides with endoglucanase activity and polynucleotides encoding them
US9493790B2 (en) 2011-08-24 2016-11-15 Novozymes, Inc. Methods for producing multiple recombinant polypeptides in a filamentous fungal host cell
US9404101B2 (en) * 2011-08-24 2016-08-02 Novozymes, Inc. Methods for obtaining positive transformants of a filamentous fungal host cell
CN108179139A (zh) 2011-08-24 2018-06-19 诺维信股份有限公司 纤维素分解酶组合物及其用途
WO2013039776A1 (fr) 2011-09-13 2013-03-21 Novozymes North America, Inc. Procédés d'hydrolyse et de fermentation de matériau cellulosique
US20140308705A1 (en) 2011-09-20 2014-10-16 Novozymes A/S Polypeptides Having Cellulolytic Enhancing Activity And Polynucleotides Encoding Same
CN103930438A (zh) 2011-09-30 2014-07-16 诺维信股份有限公司 具有β-葡糖苷酶活性的嵌合多肽和对其进行编码的多核苷酸
CA2851308A1 (fr) 2011-10-31 2013-05-10 Bp Corporation North America Inc. Utilisation de promoteurs mammaliens dans des champignons filamenteux
WO2013067026A1 (fr) 2011-10-31 2013-05-10 Bp Corporation North America Inc. Utilisation de promoteurs végétaux dans des champignons filamenteux
DK2773656T3 (da) 2011-10-31 2019-09-09 Novozymes Inc Polypeptider med cellulolyseforbedrende aktivitet og polynukleotider, som koder for dem
EP2780449B1 (fr) 2011-11-18 2018-04-11 Novozymes, Inc. Polypeptides ayant une activité bêta-glucosidase, une activité bêta-xylosidase ou une activité bêta-glucosidase et bêta-xylosidase, et polynucléotides codant pour ceux-ci
EP3597736A1 (fr) 2011-11-21 2020-01-22 Novozymes A/S Variants du polypeptide gh61 et polynucléotides codant pour ceux-ci
US9695433B2 (en) 2011-11-22 2017-07-04 Novozymes Inc. Polypeptides having beta-xylosidase activity and polynucleotides encoding same
US9624481B2 (en) 2011-12-01 2017-04-18 Novozymes, Inc. Polypeptides having beta-xylosidase activity and polynucleotides encoding same
WO2013087027A1 (fr) 2011-12-16 2013-06-20 Novozymes, Inc. Polypeptides ayant une activité laccase et polynucléotides les codant
BR112014014697A2 (pt) 2011-12-19 2020-10-27 Novozymes, Inc. polipeptídeo isolado, composição, polinucleotídeo isolado, construto de ácido nucleico ou vetor de expressão, célula hospedeira recombinante, métodos para produzir um polipeptídeo e uma proteína, para gerar oxigênio molecular, e para remover peróxido de hidrogênio do tecido, processos para degradar ou converter um material celulósico, e para produzir um produto de fermentação, e, formulação de caldo integral ou composição de cultura de células
WO2013096369A1 (fr) 2011-12-19 2013-06-27 Novozymes A/S Procédés et compositions permettant d'augmenter la digestibilité de matières cellulosiques
DK2794869T3 (en) 2011-12-20 2018-01-02 Novozymes Inc CELLOBIO HYDROLASE VARIABLES AND POLYNUCLEOTIDES CODING THEM
EP2794899A1 (fr) 2011-12-21 2014-10-29 Novozymes, Inc. Procédés de détermination de dégradation d'une matière de biomasse
CN104245929A (zh) 2012-04-23 2014-12-24 诺维信公司 具有α-葡糖醛酸糖苷酶活性的多肽以及编码其的多核苷酸
BR112014024804A2 (pt) 2012-04-23 2017-07-11 Novozymes As polipeptídeo isolado tendo atividade de glucuronil esterase, composição, polinucleotídeo isolado, construção de ácido nucleico ou vetor de expressão, célula hospedeira recombinante, métodos para a produção de um polipeptídeo, para a degradação ou conversão de um material celulósico e para a produção de um produto de fermentação
EP2841567B1 (fr) 2012-04-27 2017-07-26 Novozymes, Inc. Variants du polypeptide gh61 et polynucléotides codant pour ceux-ci
US20150210991A1 (en) 2012-09-19 2015-07-30 Novozymes, Inc. Methods For Enhancing The Degradation Or Conversion Of Cellulosic Material
US10035996B2 (en) 2012-10-08 2018-07-31 Novozymes, Inc. Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
WO2014066141A2 (fr) 2012-10-24 2014-05-01 Novozymes A/S Polypeptides ayant une activité d'amélioration cellulolytique et polynucléotides codant pour ceux-ci
WO2014070856A2 (fr) 2012-11-02 2014-05-08 Bp Corporation North America Inc. Variants de bêta-glucosidase thermotolérants
DK2925790T3 (da) 2012-11-27 2021-10-11 Novozymes As Formalingsproces
MX2015006569A (es) 2012-11-27 2015-08-05 Novozymes As Proceso de molienda.
AU2013358981A1 (en) 2012-12-14 2015-06-04 Novozymes A/S Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
US20150337280A1 (en) 2012-12-19 2015-11-26 Novozymes A/S Polypeptides Having Cellulolytic Enhancing Activity And Polynucleotides Encoding Same
CN105074001A (zh) 2013-02-21 2015-11-18 诺维信公司 糖化和发酵纤维素材料的方法
US10221406B2 (en) 2013-03-08 2019-03-05 Novozymes, Inc. Cellobiohydrolase variants and polynucleotides encoding same
WO2014145768A2 (fr) 2013-03-15 2014-09-18 Bp Corporation North America Inc. Utilisation de 5' utr non fongiques dans des champignons filamenteux
EP2994529B1 (fr) 2013-05-10 2018-11-21 Novozymes A/S Polypeptides présentant une activité xylanase et polynucléotides codant pour ceux-ci
EP3052620B1 (fr) 2013-09-04 2020-07-15 Novozymes A/S Procédés pour accroître l'hydrolyse enzymatique de matière cellulosique
CN118325984A (zh) 2013-11-01 2024-07-12 诺维信公司 糖化和发酵纤维素材料的方法
US20170166939A1 (en) 2013-11-26 2017-06-15 Novozymes A/S Enzyme Compositions and Uses Thereof
US10494655B2 (en) 2014-04-03 2019-12-03 Universiti Brunei Darussalam Synthetic fusion gene and its use thereof
US10793887B2 (en) 2014-08-21 2020-10-06 Novozymes A/S Process for saccharifying cellulosic material under oxygen addition
DK3186372T3 (da) 2014-08-28 2020-12-21 Novozymes As Solubilisering af kommunalt fast affald (MSW) ved hjælp af en enzymblanding
BR122023022768A2 (pt) 2014-09-05 2023-12-12 Novozymes A/S Variante de celobiohidrolase, polipeptídeo híbrido tendo atividade celulolítica, composição, método de produção de uma variante de celobiohidrolase ou de um polipeptídeo híbrido, método de degradação de um material celulósico e método de produção de um produto de fermentação
EP3198001B1 (fr) 2014-09-23 2021-08-11 Novozymes A/S Procédés de production d'éthanol et organismes de fermentation
WO2016120296A1 (fr) 2015-01-28 2016-08-04 Dsm Ip Assets B.V. Procédé d'hydrolyse enzymatique d'une matière lignocellulosique et de fermentation de sucres
WO2016120298A1 (fr) 2015-01-28 2016-08-04 Dsm Ip Assets B.V. Procédé d'hydrolyse enzymatique d'une matière lignocellulosique et de fermentation de sucres
ES2767554T3 (es) 2015-01-28 2020-06-17 Dsm Ip Assets Bv Proceso para la hidrólisis enzimática de material lignocelulósico y fermentación de azúcares
DK3739045T3 (da) 2015-02-24 2024-10-21 Novozymes As Cellobiohydrolasevarianter og polynukleotider, som koder for dem
WO2016145358A1 (fr) 2015-03-12 2016-09-15 Novozymes A/S Hydrolyse enzymatique avec des enzymes hémicellulolytiques
EP3268486A1 (fr) 2015-03-12 2018-01-17 Novozymes A/S Hydrolyse enzymatique multi-étape d'une biomasse lignocellulosique faisant appel à une oxydoréductase et à un polypeptide aa9
EP3067428A1 (fr) 2015-03-12 2016-09-14 BETA RENEWABLES S.p.A. Procédé de production d'un mélange hydrolysé à partir d'une pâte lignocellulosique prétraitée comprenant un liquide en suspension et des solides en suspension
DK3268484T3 (da) 2015-03-12 2020-08-17 Beta Renewables Spa Enzymatisk flertrinshydrolyse af lignocelluloseholdig biomasse
WO2016169892A1 (fr) 2015-04-20 2016-10-27 Dsm Ip Assets B.V. Procédé d'hydrolyse enzymatique d'une matière lignocellulosique et fermentation de sucres
WO2016169893A1 (fr) 2015-04-20 2016-10-27 Dsm Ip Assets B.V. Bouillon de fermentation complet
US10519520B2 (en) 2015-05-27 2019-12-31 Novozymes A/S Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
WO2016207144A1 (fr) 2015-06-22 2016-12-29 Dsm Ip Assets B.V. Procédé d'hydrolyse enzymatique de matière lignocellulosique, et de fermentation de sucres
WO2017007907A1 (fr) 2015-07-07 2017-01-12 Danisco Us Inc. Induction d'une expression génique à l'aide d'un mélange de sucres à haute concentration
CN108138153A (zh) 2015-07-24 2018-06-08 诺维信股份有限公司 具有阿拉伯呋喃糖苷酶活性的多肽以及编码它们的多核苷酸
US20180216089A1 (en) 2015-07-24 2018-08-02 Novozymes, Inc. Polypeptides Having Beta-Xylosidase Activity And Polynucleotides Encoding Same
US20180202011A1 (en) 2015-09-04 2018-07-19 Novozymes A/S Methods of inhibiting aa9 lytic polysaccharide monooxygenase catalyzed inactivation of enzyme compositions
DK3353195T3 (da) 2015-09-22 2021-11-22 Novozymes As Polypeptider med cellobiohydrolaseaktivitet og polynukleotider, der koder for dem
WO2017070219A1 (fr) 2015-10-20 2017-04-27 Novozymes A/S Variants de polysaccharide mono-oxygénase lytique (lpmo) et polynucléotides codant pour ceux-ci
CN108136452A (zh) 2015-11-02 2018-06-08 雷内科学有限公司 用混合酶溶解城市固体废物
CN109415712A (zh) 2016-03-02 2019-03-01 诺维信公司 纤维二糖水解酶变体和编码它们的多核苷酸
FI3419991T3 (fi) 2016-03-04 2023-01-31 Modifioidut ribosomaaliset promoottorit proteiinien tuottamiseksi mikro-organismeissa
CN109072209A (zh) 2016-03-24 2018-12-21 诺维信公司 纤维二糖水解酶变体和编码其的多核苷酸
WO2017205535A1 (fr) 2016-05-27 2017-11-30 Novozymes, Inc. Polypeptides présentant une activité endoglucanase et polynucléotides codant pour ceux-ci
WO2017211957A1 (fr) 2016-06-09 2017-12-14 Dsm Ip Assets B.V. Train de graines pour la production d'enzymes à grande échelle
WO2018019948A1 (fr) 2016-07-29 2018-02-01 Dsm Ip Assets B.V. Polypeptides présentant une activité améliorant la cellulolyse et leurs utilisations
WO2018026868A1 (fr) 2016-08-01 2018-02-08 Novozymes, Inc. Polypeptides présentant une activité endoglucanase et polynucléotides codant pour ceux-ci
WO2018053058A1 (fr) 2016-09-14 2018-03-22 Danisco Us Inc. Procédés basés sur la fermentation de biomasse lignocellulosique
KR102593668B1 (ko) 2016-10-04 2023-10-24 다니스코 유에스 인크. 유도 기질 부재 하의 사상 진균 세포에서의 단백질 생산
WO2018085370A1 (fr) 2016-11-02 2018-05-11 Novozymes A/S Procédés de réduction de la production de primevérose pendant la saccharification enzymatique de matière lignocellulosique
WO2018096019A1 (fr) 2016-11-24 2018-05-31 Dsm Ip Assets B.V. Composition enzymatique
WO2018096017A1 (fr) 2016-11-24 2018-05-31 Dsm Ip Assets B.V. Composition enzymatique
WO2018118815A1 (fr) 2016-12-21 2018-06-28 Dupont Nutrition Biosciences Aps Procédés d'utilisation de sérine-protéases thermostables
WO2018185071A1 (fr) 2017-04-03 2018-10-11 Dsm Ip Assets B.V. Procédé pour l'hydrolyse enzymatique de matière lignocellulosique et la fermentation de sucres
WO2019074828A1 (fr) 2017-10-09 2019-04-18 Danisco Us Inc Variants de cellobiose déhydrogénase et leurs procédés d'utilisation
SI3695001T1 (sl) 2017-10-09 2024-03-29 Versalis S.P.A. Postopek encimske hidrolize lignoceluloznega materiala in fermentacije sladkorjev
CA3078156A1 (fr) 2017-10-30 2019-05-09 Dsm Ip Assets B.V. Procede pour l'hydrolyse enzymatique de matiere lignocellulosique et la fermentation de sucres
WO2019086370A1 (fr) 2017-10-30 2019-05-09 Dsm Ip Assets B.V. Procédé pour l'hydrolyse enzymatique de matière lignocellulosique et la fermentation de sucres
WO2019089898A1 (fr) 2017-11-02 2019-05-09 Danisco Us Inc Compositions de matrices solides à point de congélation abaissé pour la granulation à l'état fondu d'enzymes
RU2020124098A (ru) 2017-12-22 2022-01-24 Новозимс А/С Способ помола пшеницы и ксиланазы gh8
WO2019185681A1 (fr) 2018-03-28 2019-10-03 Dsm Ip Assets B.V. Composition enzymatique
US11193145B2 (en) 2018-03-28 2021-12-07 Dsm Ip Assets B.V. Enzyme composition
EP3781697A1 (fr) 2018-04-20 2021-02-24 Renescience A/S Procédé de détermination de composés chimiques dans des déchets
BR112020023198A2 (pt) 2018-05-17 2021-02-09 Dsm Ip Assets B.V. processo para produção de um polipeptídeo
LT3802843T (lt) 2018-05-30 2023-04-25 Versalis S.P.A. Cukrų gamybos iš angliavandenių medžiagos būdas
WO2020058253A1 (fr) 2018-09-18 2020-03-26 Dsm Ip Assets B.V. Procédé d'hydrolyse enzymatique de matière glucidique et fermentation de sucres
WO2020058248A1 (fr) 2018-09-18 2020-03-26 Dsm Ip Assets B.V. Procédé d'hydrolyse enzymatique de matière glucidique et fermentation de sucres
WO2020058249A1 (fr) 2018-09-18 2020-03-26 Dsm Ip Assets B.V. Procédé pour l'hydrolyse enzymatique de matière glucidique et la fermentation de sucres
WO2020083951A1 (fr) 2018-10-24 2020-04-30 Dsm Ip Assets B.V. Procédé d'hydrolyse enzymatique de matière glucidique et fermentation de sucres
WO2020123463A1 (fr) 2018-12-12 2020-06-18 Novozymes A/S Polypeptides dotés d'une activité xylanase et polynucléotides codant pour ces polypeptides
WO2020127198A1 (fr) * 2018-12-21 2020-06-25 Novozymes A/S Expression de protéine en tandem
WO2020182843A1 (fr) 2019-03-12 2020-09-17 Dsm Ip Assets B.V. Procédé de production d'un bouillon de fermentation
EP4028536A1 (fr) 2019-09-10 2022-07-20 DSM IP Assets B.V. Composition enzymatique
WO2022013148A1 (fr) 2020-07-13 2022-01-20 Dsm Ip Assets B.V. Procédé de production de biogaz
CN113061189B (zh) * 2020-10-09 2022-05-27 山东省科学院生物研究所 基于cbm与纤维素特异性结合的生物传感元件
EP4240542A1 (fr) 2020-11-04 2023-09-13 Renescience A/S Procédé de désinfection de déchets
WO2022096406A1 (fr) 2020-11-04 2022-05-12 Renescience A/S Procédé de traitement enzymatique et/ou microbien de déchets comprenant la recirculation d'eau de traitement
WO2022214457A1 (fr) 2021-04-06 2022-10-13 Dsm Ip Assets B.V. Composition enzymatique
CN117178059A (zh) 2021-04-06 2023-12-05 帝斯曼知识产权资产管理有限公司 酶组合物
EP4320258A1 (fr) 2021-04-06 2024-02-14 DSM IP Assets B.V. Composition enzymatique
CN116670296A (zh) 2021-04-08 2023-08-29 维尔萨利斯股份公司 用于制备糖产品和发酵产品的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861271A (en) * 1993-12-17 1999-01-19 Fowler; Timothy Cellulase enzymes and systems for their expressions
US20030096342A1 (en) * 2001-07-28 2003-05-22 Adney William S. Thermal tolerant exoglucanase from acidothermus cellulolyticus

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1358599A (en) 1970-12-22 1974-07-03 Monacelli Umberto Gun for firing tacks
DK187280A (da) 1980-04-30 1981-10-31 Novo Industri As Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
GB2094826B (en) 1981-03-05 1985-06-12 Kao Corp Cellulase enzyme detergent composition
GB2095275B (en) 1981-03-05 1985-08-07 Kao Corp Enzyme detergent composition
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5648263A (en) 1988-03-24 1997-07-15 Novo Nordisk A/S Methods for reducing the harshness of a cotton-containing fabric
EP0406314B1 (fr) 1988-03-24 1993-12-01 Novo Nordisk A/S Preparation de cellulase
US5536655A (en) 1989-09-26 1996-07-16 Midwest Research Institute Gene coding for the E1 endoglucanase
US5110735A (en) 1989-09-26 1992-05-05 Midwest Research Institute Thermostable purified endoglucanase from thermophilic bacterium acidothermus cellulolyticus
US5275944A (en) 1989-09-26 1994-01-04 Midwest Research Institute Thermostable purified endoglucanas from acidothermus cellulolyticus ATCC 43068
EP0539395A1 (fr) * 1990-07-16 1993-05-05 Alko Group Ltd. PRODUCTION D'IMMUNOGLOBULINES PAR LES $i(TRICHODERMAS)
EP0551394A1 (fr) 1990-10-05 1993-07-21 Genencor International, Inc. Trichoderma reesei contenant de la cellulase appauvrie et/ou enrichie ainsi que d'autres genes d'enzymes et compositions de cellulase derivees
US5246853A (en) 1990-10-05 1993-09-21 Genencor International, Inc. Method for treating cotton-containing fabric with a cellulase composition containing endoglucanase components and which composition is free of exo-cellobiohydrolase I
US5475101A (en) 1990-10-05 1995-12-12 Genencor International, Inc. DNA sequence encoding endoglucanase III cellulase
FI932521A0 (fi) 1993-06-02 1993-06-02 Alko Ab Oy Nytt endoglukanasenzym
WO1994029460A1 (fr) * 1993-06-11 1994-12-22 Midwest Research Institute Heteroconjugats actifs de cellobiohydrolase et de beta-glucosidase
US6300114B1 (en) * 1994-07-29 2001-10-09 Rohm Enzyme Finland Oy Sequences of xylanase and xylanase expression vectors
US6265204B1 (en) * 1997-01-17 2001-07-24 Genencor International, Inc. DNA sequences, vectors, and fusion polypeptides for secretion of polypeptides in filamentous fungi
JP4307563B2 (ja) 1997-04-07 2009-08-05 ユニリーバー・ナームローゼ・ベンノートシャープ 糸状菌、特にアスペルギルス属に属する糸状菌のアグロバクテリウム媒介性形質転換
AU5279100A (en) 1999-05-19 2000-12-05 Midwest Research Institute E1 endoglucanase variants y245g, y82r and w42r
US7364890B2 (en) 2001-07-28 2008-04-29 Midwest Research Institute Thermal tolerant avicelase from Acidothermus cellulolyticus
US8097445B2 (en) * 2004-03-25 2012-01-17 Danisco Us Inc. Exo-endo cellulase fusion protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861271A (en) * 1993-12-17 1999-01-19 Fowler; Timothy Cellulase enzymes and systems for their expressions
US20030096342A1 (en) * 2001-07-28 2003-05-22 Adney William S. Thermal tolerant exoglucanase from acidothermus cellulolyticus

Also Published As

Publication number Publication date
BRPI0509212A (pt) 2007-08-28
JP2007530054A (ja) 2007-11-01
JP5114194B2 (ja) 2013-01-09
CN1930294A (zh) 2007-03-14
WO2005093050A3 (fr) 2006-08-24
EP2354222A1 (fr) 2011-08-10
WO2005093050A2 (fr) 2005-10-06
CA2560588A1 (fr) 2005-10-06

Similar Documents

Publication Publication Date Title
US8097445B2 (en) Exo-endo cellulase fusion protein
EP2354222A1 (fr) Protéine de fusion de cellulase et construction de fusion de cellulose hétérologue la codant
CA2520636C (fr) Cbh1.1 d'humicola grisea variant
US9523087B2 (en) Cellulase variants with improved expression, activity and stability, and use thereof
CA2770976C (fr) Homologues de cbh1 et cellulases variantes de cbh1
EP2626422A1 (fr) Compositions et procédés comprenant des variants de cellulase avec une affinité réduite pour les matières non cellulosiques
AU2014200340A1 (en) Compositions and methods comprising cellulase variants with reduced affinity to non-cellulosic materials

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061018

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

17Q First examination report despatched

Effective date: 20070116

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1101191

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1101191

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171003